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ABSTRACT 
A central question in biology is how different cell types interact with each other and 
their native environment to form complex functional systems and networks. Although our 
ability to investigate this question has considerably expanded from the development of 
genetically encoded tools, some limitations still persist. For instance, we are limited in our 
ability to visualize the native three dimensional environments of whole organs. Additionally, 
it is challenging to efficiently deliver transgenes into difficult-to-target areas through direct-
injections, such as the cardiac ganglia, or broadly distributed networks, such as the myenteric 
nervous system, which limits our ability to extensively study these areas. Therefore, tools 
and methods that overcome these limitations are needed. Towards this end, my thesis work 
has been focused on developing tools for single-cell resolution phenotyping in whole organs. 
I have been developing tissue clearing technologies to render whole organs transparent for 
optical interrogation and characterizing viral capsids and engineering viral vectors for 
noninvasive widespread gene delivery to the central and peripheral nervous system.  
Tissue clearing techniques for three dimensional optical interrogation were invented 
over a century ago. However, these earlier methods used harsh organic chemicals and failed 
to retain the tissue’s native fluorescence or epitopes. These earlier methods eventually 
became incompatible to the hundreds of newly generated transgenic mouse lines that allowed 
for cell type-specific expression of fluorescent transgenes or to fluorescent labeling 
techniques, such as immunohistochemistry (IHC).  The first part of my dissertation is aimed 
at addressing these limitations by further developing and standardizing a tissue clearing 
method that utilizes the vasculature to perfuse clearing reagents. This technique, called 
perfusion assisted agent release in situ (PARS) enables (i) whole organ clearing of soft tissue, 
(ii) preservation of native fluorescence, and (iii) preservation of epitopes compatible with 
IHC.  
Although PARS allows us to optically investigate whole soft tissue organs, it is 
unsuitable for clearing bone tissue. The clearing of bone is important as it may provide 
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optical access to delicate environments, such as the lymphatic vessels lining the dural sinuses 
beneath the skull that would otherwise be damaged through traditional methods. However, 
clearing bone tissue is challenging since it is composed of both soft (bone marrow) and hard 
(mineral) tissue. To overcome this challenge, I developed a clearing method that rendered 
intact bone tissue transparent by using EDTA to decalcify bones and by constructing a 
convective flow chamber to efficiently clear bones. This method, called Bone CLARITY, is 
able to preserve native fluorescence and epitopes. In order to demonstrate the utility of Bone 
CLARITY, I collaborated with colleagues to quantitatively access a rare and non-uniformly 
distributed population of osteoprogenitor cells in their native three dimensional environment. 
Bone CLARITY in conjunction with light-sheet microscope enabled the early detection of 
an increase to this osteoprogenitor population after administration of a novel anabolic drug, 
which may have been undetected with traditional techniques. 
Towards my second goal, I have been working on characterizing adeno-associated 
viruses (AAVs) for non-invasive widespread gene delivery across the central or peripheral 
nervous system. Through systemic delivery, these novel AAVs are able to efficiently deliver 
transgenes to (i) difficult-to-target areas, such as the dorsal root ganglia; (ii) cellular 
populations that are widely distributed across the mouse body, such as neurons in the 
myenteric nervous system, and (iii) through highly selective barriers, such as the blood-brain 
barrier. These viruses enable rapid expression of transgenes for perturbing and monitoring 
cellular circuits, or for potentially treating neurological diseases. In addition, I worked on 
engineering or validating several different gene regulatory elements to achieve cell type 
restricted expression in transgenic and non-transgenic animals with AAVs. These viral 
vectors may prove useful in rapidly testing newly developed genetic tools. Finally, I 
developed and characterized two different two-component viral vector systems to control the 
density of labeling when systemically delivering genes with our novel engineered viruses. I 
utilized this two-component system to perform single-cell morphology studies in the CNS 
and PNS. Collectively, these capsids and vectors expand the AAV toolbox and enable 
efficient and versatile gene delivery into the CNS and PNS of transgenic and non-transgenic 
animals.  
viii 
 
 
PUBLISHED CONTENT AND CONTRIBUTIONS 
[1] Chan, K.Y.C et al. “Engineered adeno-associated viruses for efficient and noninvasive gene 
delivery throughout the central and peripheral nervous systems”. In press. 
K.Y.C helped design and perform experiments, collect and analyze data, prepare figures and 
write the manuscript with input from all authors 
 
[2] Greenbaum, A. et al. “Bone CLARITY: Clearing, imaging, and computational analysis of 
osteoprogenitors within intact bone marrow”. In: Science Translational Medicine 387.9 (2017). 
URL: http://doi.org/10.1126/scitranslmed.aah6518.  
K.Y.C. performed experiments, data acquisition, data analysis, generated figures, and wrote the 
manuscript with input from all authors. 
 
[3] Allen, W. et al. “Global Representations of Goal-Directed Behavior in Distinct Cell Types of 
Mouse Neocortex”. In: Neuron 94.4 (2017), pp. 891-907. 
URL:http://dx.doi.org/10.1016/j.neuron.2017.04.017. 
K.Y.C. prepared AAV-PHP.B viruses. 
 
[4] Xiao, C. et al. “Cholinergic Mesopontine Signals Govern Locomotion and Reward through 
Dissociable Midbrain Pathways”. In: Neuron 90.2 (2016), pp. 333-347. URL: 
http://doi.org/10.1016/j.neuron.2016.03.028 
K.Y.C. contributed to animal behavior tests and data illustration. 
  
[5] Deverman, B.E. et al. “Cre-dependent selection yields AAV variants for widespread gene 
transfer to the adult brain”. In: Nature Biotechnology 34.2 (2016), pp. 204-209. doi: 
10.1038/nbt.3440.  
K.Y.C. performed experiments, virus production and characterization. 
 
[6] Treweek, J.B. et al. “Whole-body tissue stabilization and selective extractions via tissue-
hydrogel hybrids for high-resolution intact circuit mapping and phenotyping”. In: Nature 
Protocols 10.11 (2015), pp. 1860-1896. doi:10.1038/nprot.2015.122. 
K.Y.C designed and performed experiments, analyzed the data and prepared figures. 
 
[7] Skennerton, C.T. et al. “Genomic reconstruction of an uncultured hydrothermal vent 
gammaproteobacterial methanotroph (family Methylothermaceae) indicates multiple adaptations 
to oxygen limitation”. In: Frontiers in Microbiology 23.6: 1425 (2015). doi: 
10.3389/fmicb.2015.01425. URL: https://doi.org/10.3389/fmicb.2015.01425 
K. Y.C performed laboratory work to prepare samples for sequencing 
 
[8] Flytzanis, N.C. et al. “Archaerhodopsin variants with enhanced voltage-sensitive 
fluorescence in mammalian and Caenorhabditis elegans neurons”. In: Nature Communications 
15.5: 4894 (2014). doi:10.1038/ncomms5894. 
K.Y.C. performed experiments. 
  
ix 
 
 
Table of contents 
Acknowledgments…………………………………………………………... iii 
Abstract ………………………………………………………………………vi 
Published Content and Contributions……………………………………......viii 
Table of Contents……………………………………………………………. ix 
Chapter I: Introduction ........................................................................................ 1 
1.1 Technology development for the study of biological systems ............... 1 
1.2 Tissue clearing for whole organs using the vasculature ......................... 2 
1.3 Developing tissue clearing to render whole bone transparent ............... 3 
1.4 1.4 Characterizing adeno-associated viral capsids and engineering viral 
vectors ............................................................................................................ 5 
Chapter II: Whole-body tissue stabilization and selective extractions via tissue-
hydrogel hybrids for high-resolution intact circuit mapping and phenotyping . 8 
2.1 Summary .................................................................................................. 8 
2.2 Building a PARS chamber ...................................................................... 8 
2.3 Standardized Procedure for PARS ........................................................ 10 
2.4 Main Figures .......................................................................................... 12 
Chapter III: Bone CLARITY: clearing, imaging, and computational analysis 
of osteoprogenitors within intact bone marrow ................................................ 15 
3.1 Summary ................................................................................................ 15 
3.2 Introduction ........................................................................................... 16 
3.3 Results .................................................................................................... 18 
3.4 Discussion .............................................................................................. 24 
3.5 Main figures ........................................................................................... 27 
3.6 Supplementary Figures .......................................................................... 34 
3.7 Supplementary movie captions ............................................................. 45 
3.8 Materials and methods .......................................................................... 46 
3.9 Supplementary methods ........................................................................ 49 
3.10 Additional information ........................................................................ 54 
Chapter IV: Engineered adeno-associated viruses for efficient and noninvasive 
gene delivery throughout the central and peripheral nervous systems............. 55 
4.1 Summary ................................................................................................ 55 
4.2 Introduction ........................................................................................... 56 
4.3 Results .................................................................................................... 58 
4.4 Discussion .............................................................................................. 64 
4.5 Main Figures .......................................................................................... 68 
4.6 Supplementary figures ........................................................................... 78 
4.7 Supplementary tables ............................................................................ 91 
4.8 Supplementary movie caption ............................................................... 93 
4.9 Methods ................................................................................................. 94 
4.10 Additional information ...................................................................... 100 
Bibliography .................................................................................................... 102 
1 
 
 
C h a p t e r  1  
INTRODUCTION 
1.1 Technology development for the study of biological systems 
Scientific discoveries are not only dependent on new and novel ideas or conceptual 
leaps that result in paradigm shifts, but also in advances to the technologies that make these 
steps possible. Tools that enable viewing or manipulation of biological systems have 
accelerated efforts in our understanding of complex biological processes by allowing 
researchers to visualize or perturb these events. Some of the most important and widely 
adopted biological tools are simple, elegant, and have revolutionized the way we perform 
research. One classic example of this is the discovery and usage of green fluorescent protein 
in E. coli and C. elegans. Since its publication, it has allowed researchers to peer into the 
inner workings of biological environments. Another example of this are the tools in 
optogenetics, where the use of light-activated bacterial proteins have allowed researchers to 
perturb biological circuits and dissect out their function with high spatial and temporal 
resolution in genetically defined populations of cells1. These examples highlight the 
importance of tool development in the study of biological systems. As the complexity of 
biology unravels, the demand for more advanced tools and techniques rises, and 
consequently, tool developers will need to adapt to this demand in order to further push 
discoveries with novel approaches. Limited to our current repertoire of tools, are those that 
allow for visualization of native three dimensional environments. Additionally, it is 
challenging to deliver transgenes into difficult-to-access areas, such as the cardiac ganglia, 
or broadly distributed networks, such as the myenteric nervous system, which limits our 
ability to extensively study these areas. Therefore, technological tools that overcome these 
limitations are in need. 
The body of work summarized in this dissertation has been focused on developing 
tools in addressing a central question in biology: how different cell types interact with each 
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other and their native environment to form complex functional systems and networks. These 
tools include (i) developing tissue clearing methods to render tissue transparent for three-
dimensional optical interrogations, (ii) expanding the adeno-associated viruses (AAV) 
toolbox by characterizing capsids for non-invasive widespread gene delivery throughout the 
CNS and PNS, (iii) generating or validating gene regulatory elements for cell type-specific 
expression of transgenes in non-transgenic animals, and (iv) developing viral vectors for 
sparse multi-color gene expression for single-cell morphology studies. Collectively, the 
developed tissue clearing methods, characterized novel viruses, and engineered viral vectors 
allow for single-cell resolution phenotyping in whole organs and will help further our 
understanding of complex biological systems and networks. 
1.2 Tissue clearing for whole organs using the vasculature  
The ability to visualize biological tissue has long been appreciated by scientists. That 
is why tools like microscopes and microtomes have been indispensable in research. They 
allow us to view physical evidence of cellular components and processes in two-dimensional 
sections. But recently, with the growing ability to handle and process bigger data sets, more 
advanced microscopes being built (i.e., objectives with longer working distances and light-
sheet microscopy allowing for faster acquisition times), and multidisciplinary approaches to 
tackle on scientific questions on a larger scale, it is no surprise that there is a trend to 
investigate biological tissue in three dimensions to better understand how cells interact with 
each other and their native environment. The brain is a prime example that represents the 
complexity of an organ and the need to study it in three dimensions. Neurons can project 
long distances and branch in many different directions to form intricate neural networks. 
However, the idea of rendering tissue transparent for three-dimensional optical access has 
been around for over a century. For example, solvent-based clearing methods, such as benzyl 
alcohol, was first described by Spalteholz over one hundred years ago2.  Since then, many 
solvent-based variations have been published to render tissue transparent. These methods 
were able to produce samples that were novel at the time and allowed unprecedented optical 
access to study anatomy. However, major limitations to solvent-based clearing were the 
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inability to perform immunostaining, preserve native fluorescence, and risks damage to the 
tissue from the use of harsh chemicals3. With the ever growing number of transgenic reporter 
mouse lines and tools that genetically targeted cells with fluorescent proteins it was only a 
matter of time until researchers would come up with ways to render tissue transparent while 
preserving the ability to perform immunostaining and native fluorescence. The hurdle was 
crossed in 2013 when Chung K. et al. published the CLARITY technique4 allowing the 
ability to immunostain and preserve native fluorescence. CLARITY utilized a hydrogel mesh 
that locked the proteins in their original positions while removing lipids from the tissue. 
Lipids are the main organic material that prevents imaging deep into tissue because of their 
light-scattering properties. However, a caveat to CLARITY was the use of an electric current 
to speed up the lipid removal process and penetration of antibodies. The use of this electric 
current caused the tissue to heat up and turn brown mainly due to the Maillard reaction. 
CLARITY also required expensive equipment, such as platinum wires and a commercial 
refractive index matching solution, which limited its wide adoption. Ultimately, researchers 
aimed to expand upon the CLARITY approach by avoiding the use of the electric current 
and also making the procedure more adoptable. In Chapter 2, I present tissue clearing work 
where I aimed to develop and optimize ways to perform rapid whole organ clearing of soft 
tissue using the vasculature, an idea published in the lab5 but its procedure was not yet 
optimized. I standardized this procedure by detailing a step-by-step protocol and also 
outlined how to easily build an affordable clearing chamber with common and readily 
available parts found in a molecular laboratory. By using the vasculature, the use of an 
electric current could be avoided while still maintaining a rapid clearing time. In addition, 
small molecular dyes and antibodies could be perfused through to allow for immunostaining. 
This work is summarized in Chapter 2.  
1.3 Developing tissue clearing to render whole bone transparent for single-cell 
phenotyping 
Since the publication of CLARITY and the proceeding clearing methods (uDISCO6, 
CUBIC7, PACT5, PARS5, ScaleSQ8), there was growing interest in adopting clearing 
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technology for the study of bone. There were two main reasons why this was important in 
relation to neuroscience. The first came from a paper in 2015 that detailed the discover of 
lymphatic vessels beneath the skull lining the dural sinuses9. Access to these areas beneath 
the skull through traditional means is difficult. They are readily damaged with even low 
amounts of force. Therefore, the study of such lymphatic vessels were difficult and for a long 
time overlooked. Methods that can study these areas of interest without disruption to the 
native environment could prove useful in fields like neuroimmunology and may help shed 
insight into how immune system dysfunction is associated with neurodegenerative diseases. 
The second reason came from the fact that bone contributes to whole-organism physiology. 
They regulate calcium levels, energy metabolism, and provide structural support10. 
Interestingly, there also exists a bone-brain axis that regulates appetite11. Therefore, the 
importance of bone to whole-organism physiology and accessing the delicate interfaces 
housing unique environments was a large motivation in developing tissue clearing 
technology to study bone. However, the challenge with bone is that it is a complex tissue; it 
contains both soft tissue (marrow) and hard tissue (minerals). At the time, tissue-clearing 
protocols were designed for soft tissue only, such as the brain. Consequently, a clearing 
protocol would need to be designed specifically for clearing bones. The goal was to develop 
a way to clear bone tissue while maintaining the native fluorescence of reporter mouse lines. 
This involved removing hard minerals from bones by decalcifying them with a chelating 
agent before lipid removal. In addition, since bone harbors a large amount of heme that 
autofluorescence, an amino alcohol was used to remove the heme. After I had developed a 
bone-clearing protocol, I collaborated with colleagues to use tissue clearing for bones to 
answer a biologically relevant question. I worked alongside Dr. Greenbaum in imaging intact 
bones with a custom-built light-sheet fluorescence microscope that minimized acquisition 
times compared to conventional point scanners microscopes. Together, we were able to 
image native fluorescence in whole bones at single-cell resolution to study a rare and non-
uniform population of osteoprogenitor cells. I also worked with two young collaborators to 
build computation tools for semi-automated cell quantification of these rare and non-
uniformly distributed osteoprogenitor cells. We found after administration of a novel 
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anabolic drug, we were able quantitatively detect a minute increase in the osteoprogenitor 
population of cells. We demonstrated that this minor increase may have been undetected 
using traditional methods until later time points due to sub-sampling errors from statistical 
estimation. This highlighted the sensitivity of our methods.  The summary of this work is 
found in Chapter 3.  
1.4 Characterizing adeno-associated viral capsids and engineering viral vectors  
The process of introducing foreign DNA into a cell is one of the most fundamental 
techniques in biology. It allows researchers to manipulate a cell’s phenotype for study or 
treatment.  There are many ways to achieve gene transfer in vivo: electrically 
(electroporation), mechanically (microinjection), synthetically (nanoparticles), or 
biologically (viruses), to name a few. There is no gold-standard way, and each of the listed 
methods has its pros and cons. Nevertheless, the methods listed are well-established 
techniques and widely adopted in research. However, if there were a gold standard for in vivo 
gene transfer, it would probably be something that was: non-invasive, had a high transduction 
efficiency, with either broad or specific tropisms, have low immunogenicity, with the ability 
to deliver large-sized genomes, be cost efficient to produce, and allowed for long-term 
expression without host genome integration. With no surprise, various viruses have evolved 
from nature that are able to satisfy a moderate amount of these requirements, but not all. For 
example, herpes simplex virus HSV allows for large packaging of genomes and allows for 
fast expression in neuronal cells; however, HSVs can cause an acute inflammatory 
response12. Lenti viruses, on the other hand, have a modest packaging capacity and can 
transduce dividing and non-dividing cells, but generally contain impurities in their envelope, 
making them difficult to purify which causes an acute inflammatory responses13. 
Recombinant adeno-associated viruses (rAAVs) have a small packaging capacity compared 
to other viruses; however, their ability to provide safe and moderate levels of long-term 
expression in a wide array of cell types has made them an attractive gene delivery tool in 
basic research and clinical trials14. For example, in 2012, the first AAV gene therapy was 
approved by the European Commission for the treatment of lipoprotein lipase deficiency15. 
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This was a major milestone for viral gene therapy. Although AAVs are widely adopted in 
research and preclinical trials nowadays, their full potential is only beginning to unravel. 
Within the AAV platform, there is a lack of AAVs that can provide broad and non-invasive 
gene transfer to difficult-to-access environments (i.e., dorsal root ganglion, cardiac ganglia) 
or widely distributed organs (brain, enteric nervous system). In addition, the main delivery 
method of AAVs is through site-directed injections, which for most applications is suitable 
and desirable to restrict expression of a transgene. However, for applications, such as gene 
therapy in neurological diseases within the central nervous system (CNS), where likely 
multiple brain regions are affected, the current repertoire of AAVs would require numerous 
site-directed injection due to their poor transduction efficiency during systemic delivery. 
Furthermore, for basic research, the ability for widespread gene delivery could allow 
researchers to more rapidly test new molecular tools, such as voltage indicators, and refine 
those tools before dedicating the time and cost in generating a transgenic mouse line. In 
addition, AAVs that could delivery genetic tools into difficult-to-target areas could help in 
our studies in understanding these areas. From the already desirable properties of AAVs, it 
wasn’t surprising that researchers focused on improving the versatility of the AAV platform. 
For example, researchers have engineered AAVs with more specific tropism to endothelial 
cells16 in the CNS or to have enhanced transduction efficiency into the CNS 17 through 
systemic delivery. In 2016, Deverman et al. published AAV-PHP.B using a capsid selection 
method, called Cre recombination–based AAV targeted evolution (CREATE)18. AAV-
PHP.B allowed for the ability to deliver genes across the central nervous system (CNS) non-
invasively with a 40-fold higher transduction efficiency than the current standard, AAV9, at 
the time. Such AAVs may prove to be important for the treatment of neurological diseases 
where the replacement of a defective gene in the entire central nervous system would require 
widespread non-invasive gene delivery. However, much work is still required to improve 
these new novel AAVs. For example, AAVs with efficient non-invasive delivery into the 
peripheral nervous system (PNS) are lacking. These AAVs could be useful for the delivery 
of genes into areas that are difficult-to-target surgically, such as the dorsal root ganglia, for 
the study of pain. In addition, high viral payloads for efficient widespread transduction 
7 
 
 
through systemic delivery are still required. The ability to maintain a high transduction 
efficiency with a lower viral payload could be useful in several ways. The first is lowering 
viral payloads could help bypass neutralizing antibodies in the organism when high viral 
payloads are used. The second is more practical: lower viral payloads with high transduction 
efficiency will help in reducing the cost and time burden in viral production when scaling up 
for larger model organisms or preclinical trials.  The viral work presented in this thesis is 
focused on the characterization of novel AAVs for efficient and noninvasive gene delivery 
throughout the CNS and PNS. The work is based off the CREATE method and uses it to 
further evolve the AAV-PHP.B capsid towards more efficient transduction in neurons at 
lower viral payloads. It also involves the characterization of a new capsid that showed high 
transduction efficiency towards peripheral sensory neurons. Viruses that can transduce 
sensory neurons widely distributed, such as those found in the enteric nervous system, are 
lacking, so this variant may prove useful in accelerating research in newly developing multi-
system fields, such as the gut-brain axis19. In addition, I present my work in developing viral 
vectors for single-cell phenotyping in whole-organ systems. This was done by using our 
novel AAVs with engineered viral vectors I constructed to allow for sparse multicolor 
labeling of cells in a ubiquitous or cell type-specific manner. The idea of using multicolor 
for cell tracing and morphology studies is not novel. It was first published in 2007 by Livet 
J et. al, and afterwards, several iterations20 were made to improve its approach. However, a 
major limitation to the approach was the lack of ability to modulate its density in labeling, 
something difficult to achieve with transgenic animals or site-directed injections of viruses. 
To overcome this, I worked on building and testing two different two-component systems 
using Flp recombinase or the tetracycline inducible system for modulating the density of 
labeling with our systemically deliverable viruses. I utilized this system to study cell 
morphology in the CNS and PNS. Finally, in order to further maximize the utility of AAVs, 
I also constructed or validated several different gene regulatory elements for cell type specific 
expression in non-transgenic animals. Collectively, this expansion of the AAV toolbox 
enables efficient and versatile gene manipulation in the CNS and PNS of transgenic and non-
transgenic animals. This work is summarized in Chapter 4 of my thesis.  
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C h a p t e r  2  
Whole-body tissue stabilization and selective extractions via tissue-hydrogel 
hybrids for high-resolution intact circuit mapping and phenotyping 
[6] Treweek, J.B. et al. “Whole-body tissue stabilization and selective extractions via tissue-
hydrogel hybrids for high-resolution intact circuit mapping and phenotyping”. In: Nature 
Protocols 10.11 (2015), pp. 1860-1896. doi:10.1038/nprot.2015.122. 
 
2.1 Summary 
To facilitate fine-scale phenotyping of whole specimens, we describe here a tissue 
fixation-embedding, detergent-clearing and staining protocol that can be used to transform 
whole organisms into optically transparent samples within 1–2 weeks without compromising 
their cellular architecture or endogenous fluorescence. The method perfusion-assisted agent 
release in situ (PARS) is optimized and standardized in this chapter for whole-body tissue 
clearing of soft tissue. It uses a hydrogel to stabilize tissue biomolecules during selective 
lipid extraction, resulting in enhanced clearing efficiency and sample integrity. Furthermore, 
the macromolecule permeability of PARS-processed tissue hybrids supports the diffusion of 
immunolabels throughout intact tissue, whereas RIMS (refractive index matching solution) 
grants high-resolution imaging at depth by further reducing light scattering in cleared and 
uncleared samples alike. The protocol and solutions outlined enable phenotyping of 
subcellular components and tracing cellular connectivity in intact biological networks. 
 
2.2 Building a PARS chamber 
To perfuse PARS reagents through vasculature in a contained environment, we 
construct a PARS chamber using components that are readily found in most of the 
biological research laboratories (Figure 2.1). The necessary components of a PARS setup 
are as follows: a feeding needle catheter to deliver PARS reagents to vasculature; a 
perfusate catch-basin (pipette box) in which recirculating PARS reagents may pool once 
they exit the vasculature;-Tygon tubing threaded through a peristaltic pump so that pooling 
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reagents may be collected from the catch-basin and recirculated back into a subject's 
vasculature; Luer-to-tubing couplers; and a Ziploc bag to contain the entire PARS chamber 
setup. 
To construct the PARS chamber, drill two 1/8-inch holes into the front and one 1/8-
inch hole into the left side wall of an empty 1,000-μl pipette tip box. The holes are drilled 
just below the tip wafer (in Figure 2.1, the holes are ~2 cm below the top rim). Next, snap 
1/8 × 1/8-inch barbed connectors into each of the drilled holes. The outflow line will 
circulate solvents from the pipette box chamber to the 3-way stopcock. To join the outflow 
line to a 3-way stopcock, use a 10-cm piece of Tygon tubing and connect one end to the 
inner left side 1/8 × 1/8-inch barbed connector and tape the other end to the inside bottom 
of the pipette tip box. Continue this line through a peristaltic pump by using a new piece 
of Tygon tubing, and connect one end to the outer left side 1/8 × 1/8-inch barbed connector 
and then thread the tubing through a peristaltic pump. Next, join the free end to a three-
way stopcock with a 3/32-inch barbed male Luer with locking nut. The inflow line 
circulates solvents from the three-way stopcock to the vasculature. To link the inflow line 
to the pipette tip box, use a piece of 15-cm Tygon tubing and connect one end to the outer 
right front 1/8 × 1/8-inch barbed connector and the other end to the three-way stopcock 
with a 3/32-inch barbed male Luer with locking nut. To finish the inflow line, connect a 
piece of 75-cm Tygon tubing to the inner right front 1/8 × 1/8-inch barbed connector. Next, 
coil the inflow line to the bottom of the pipette tip box. This will equilibrate inflowing 
solvent to the desired temperature before it enters the subject's vasculature. Tape the coiled 
tubing to the pipette tip box. To quickly circulate bubbles formed during the changing of 
solutions without disconnecting the inflow line and for use of bubbling nitrogen gas into 
the solution during the polymerization step, a line linking the outflow line back to the 
pipette tip box is connected by joining a piece of 15-cm Tygon tubing to the three-way 
stopcock with a full-thread 3/32-inch barbed female Luer to the outer left front 1/8 × 1/8-
inch barbed connector. This line is continued inside the pipette tip box and taped to the 
bottom. To finish the chamber, thread the inflow line through the top-left corner of the tip 
wafer and connect it to a feeding tube with a 1/8-inch barbed male slip Luer. As a 
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forewarning, SDS and salt precipitate will begin to accumulate within these narrow lines 
over time. It is important to flush the lines (e.g., with ddH2O) between subjects, and to 
replace occluded lines with new Tygon tubing (e.g., after every few subjects). 
During hydrogel polymerization, the chamber must be enclosed inside a Ziploc 
freezer bag. To do this, disconnect the outer Tygon tubing that connects to the barbed 
connectors of the pipette tip box, and puncture three holes into the Ziploc bag to 
accommodate the 1/8 × 1/8-inch barbed connectors. Reconnect the Tygon tubing to their 
original 1/8 × 1/8-inch barbed connector. To connect a vacuum line to this bagged PARS 
box for withdrawing oxygen, tape a female Luer tee onto the lid of the pipette box and 
puncture one hole through the Ziploc. Finally, make the Ziploc airtight by placing clay 
around the punctured regions in the Ziploc. 
As a final note, a 1,000-μl tip box has a volume of ~750 ml. Thus, during hydrogel 
polymerization and during clearing, 200–300 ml of solution may be placed in the pipette 
box for recirculation without risk of the pipette box overflowing or the solution splashing 
out during its transport. Similarly, to conserve reagents during PARS clearing and 
immunostaining of smaller samples, a 200-μl tip box may be used to construct the PARS 
chamber; only 100 ml of reagent is necessary to fill such a chamber about one-third full 
(Figure 2.1).  
2.3 Standardized Procedure for PARS 
After polymerization, wash the perfusion lines with 1× PBS, and then replace the 
wash buffer with 8% SDS-PBS (pH 7.5) clearing buffer. This procedure can be accomplished 
easily by removing the PARS chamber from the shaking water bath (optional), by turning 
off the pump, by removing excess initiator buffer from the PARS chamber and by replacing 
it with 100 ml of 1× PBS to perform the wash. Circulate the wash buffer through the sample 
for 10 min. Afterward, replace the buffer with 8% SDS-PBS (pH 7.5). Place the chamber 
back into the Ziploc bag and into the 37–42 °C water bath. Allow the SDS clearing buffer to 
recirculate through the system for 24 h. Perform a buffer exchange with fresh 8% SDS-PBS 
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(pH 7.5), by clearing the buffer daily until the recirculated fluid is no longer yellowish, after 
which the SDS solution can be refreshed less frequently (every 48–72 h). 
Check on the clearing progress daily. Add additional SDS buffer to the PARS 
chamber if necessary, as depending on how well the Ziploc bag is sealed around the perfusion 
tubing, some buffer may evaporate over time. 
The sample can be continuously perfused for up to 2 weeks until all desired organs 
have cleared, even if some organs appear clear within the first 24–48 h. Alternatively, if all 
but one or two organs appear sufficiently transparent after a few days, one may proceed 
directly to Step 7C(iv) to flush SDS from tissue, and then excise all organs. The one or two 
semiopaque excised organs are transferred into 8% (wt/vol) SDS to finish clearing via PACT, 
whereas the organs that cleared more rapidly are immediately promoted to passive 
immunostaining (optional) and mounting without further delay.  
For samples that will be immunolabeled after clearing, the hydrogel matrix will be 
required to support the cleared tissue for several rounds of washing and multiday incubations 
with gentle shaking. If the already delicate tissue-hydrogel matrix seems precariously fragile 
after clearing (this usually only occurs with thin-sectioned tissue), it is advisable to repeat 
the hydrogel embedding and polymerization steps. This will stabilize tissue architecture 
during immunolabeling, prevent tissue loss or disintegration and counteract expansion in 
mounting medium. For cleared samples that will not undergo any immunohistochemical 
labeling steps before imaging. The ending results are in (Figure 2.2)  
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2.4 Main Figures 
 
Figure 2.1. Assembling and working with the PARS chamber. (a) A completed PARS 
chamber used for whole-body tissue clearing. (b) Individual parts to build a PARS 
chamber: (1) three 1/8 × 1/8-inch barbed connectors, (2) two 3/32-inch barbed male Luers 
with locking nut, (3) a 1,000 µl pipette tip box, (4) a 1-gallon Ziploc freezer bag, (5) a 
three-way stopcock with Luer lock, (6) a 3/32-inch barbed female Luer with full tread, (7) 
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a roll of lab tape, (8) a 22-G × 1-inch gavage needle, (9) a 1/8-inch barbed male slip Luer, 
(10) a female Luer tee with locks, (11) clay and (12) Tygon E-lab tubing. Ruler shown is 
5 cm in length. (c) Three 1/8-inch holes are drilled into the pipette tip box: two into the box 
front and one into its side, all ~2 cm below the top rim of the box. The three 1/8 × 1/8-inch 
barbed connectors are placed into the drilled holes. To connect the outflow line (blue tape 
bands on outflow line tubing), a piece of Tygon tubing is connected from the bottom inside 
of the pipette box to the single 1/8-inch barbed connector that was inserted through the box 
side. (d) To continue the outflow line, a second, longer piece of blue-taped tubing is 
attached to the outer fitting of this same barbed connector (on the outside of the pipette tip 
box side), and then the other end of this tubing is threaded through the peristaltic pump, 
pulled back over toward the pipette box and finally connected to a three-way stopcock with 
a 3/32-inch barbed male Luer with locking nut (rightmost blue-banded tubing in d). To 
form the inflow line, a short length of tubing (green tape band) is used to connect the three-
way stopcock to the front right 1/8-inch barbed connector of the pipette box. The solute 
flushing line and nitrogen bubbling line, which are subserved by the same tubing (white 
tape band), are formed by another short length of tubing that joins the third port of the 
stopcock to the front left 1/8-inch barbed connector. (e) The inflow line is continued inside 
the pipette box, with the tubing coiled several times around the base of the box so that the 
solute will be reheated before it passes through the feeding gavage into the subject. The 
solute flushing line and nitrogen bubbling line is continued inside the pipette tip box and 
taped to the bottom of the chamber (not shown). (f) The tip of the coiled inflow line tubing 
is threaded up through the tip wafer (see bird’s-eye view of threaded wafer in a) and 
connected to a 22-G ×1-inch gavage needle with a 1/8-inch barbed male slip Luer. The 
gavage needle is secured with a short loop of Tygon tubing (~90 mm) threaded through 
two holes of the wafer. (g) During the polymerization step, the chamber is placed into a 37 
°C water bath and sealed in a Ziploc bag. The tubing is attached to the chamber with three 
1/8 × 1/8-inch barbed connectors punctured through the Ziploc bag. The Tygon tubing is 
reconnected from the outside of the bag and surrounded with clay to make an airtight seal. 
(h) The animal is placed onto the pipette tip box, and the 22-G × 1-inch gavage needle is 
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used to catheterize the heart. (i) The chamber is placed into a 37 °C water bath. A female 
Luer tee, which is taped onto the lid of the pipette tip box, is punctured through the Ziploc 
bag, and this joint is sealed with clay to ensure an airtight seal. Finally, to accelerate 
polymerization, a vacuum line is connected to the female Luer tee to remove oxygen 
(orange arrow), and a nitrogen gas line (white arrow) is connected to the 1/8-inch barbed 
connector to deliver a steady flow of nitrogen into the bagged system. The solute is 
continually circulated through the animal from the outflow line (blue arrow, which also 
indicates the direction of flow through blue-taped tubing) and inflow line (green arrow, 
which also indicates the direction of flow through green-taped tubing). 
 
 
Figure 2.2. Whole-body clearing of mice with PARS. (a) A4P0-hybridized organs shown 
before the start of clearing (left) and after 5 d of clearing with 8% SDS-PBS (pH 8.5) and 
overnight washing with 1× PBS at pH 7.5 (right). Numbers correspond to the extracted 
organs in b. (b) Extracted organs from the cleared mouse in a, pictured before (top) and 
after (bottom) RIMS incubation for 3 d. Black pointers correspond to the adrenal gland on 
the kidney and to the ovaries on the fallopian tubes. Each square represents 0.5 cm2. Rodent 
husbandry and euthanasia conformed to all relevant governmental and institutional 
regulations; animal protocols were approved by the Institutional Animal Care and Use 
Committee (IACUC) and by the Office of Laboratory Animal Resources at the California 
Institute of Technology.  
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C h a p t e r  3  
Bone CLARITY: clearing, imaging, and computational analysis of 
osteoprogenitors within intact bone marrow  
 
[2] Greembaum, A. et al. “Bone CLARITY: Clearing, imaging, and computational analysis 
of osteoprogenitors within intact bone marrow”. In: Science Translational Medicine 387.9 
(2017). URL: http://doi.org/10.1126/scitranslmed.aah6518.  
 
3.1 Summary 
 
Bone tissue harbors unique and essential physiological processes such as 
hematopoiesis, bone growth, and bone remodeling. To enable visualization of such 
processes at the cellular level in an intact environment, we developed “Bone CLARITY”, 
a bone tissue clearing method. We used Bone CLARITY and a custom-built light-sheet 
fluorescence microscope (LSFM) to detect the endogenous fluorescence of Sox9-
tdTomato+ osteoprogenitor cells in the tibia, femur, and vertebral column of adult 
transgenic mice. To obtain a complete distribution map of these osteoprogenitor cells, we 
developed a computational pipeline that semi-automatically detects individual Sox9-
tdTomato+ cells in their native 3D environment. Our computational method counted all 
bone cells without relying on sampling techniques and displayed increased precision when 
compared with traditional stereology techniques for estimating the total number of rare 
cells. We demonstrate the value of the clearing–imaging pipeline by quantifying changes 
in the population of Sox9-tdTomato labeled osteoprogenitor cells following sclerostin 
antibody treatment. Bone tissue clearing is able to provide fast and comprehensive 
visualization of biological processes in intact bone tissue. 
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3.2 Introduction 
The mammalian skeletal system consists of numerous bones of varying shapes and 
sizes that provide support to the body and protect internal organs from external physical 
stress21,22. Different bone types harbor specialized physiological processes that are key for 
proper development and survival of the organism, such as replenishment of hematopoietic 
cells, growth, and remodeling of the bone during healthy and diseased states23,24 25,26. 
Traditionally, these processes have been investigated through methods that provide zero- 
or two-dimensional information, such as fluorescence activated cell sorting (FACS) or 
analysis of histological sections. Quantitative 3D data of geometric features such as volume 
and number of cells, can be obtained from histological sections with unbiased stereological 
methods. Although statistically robust, such methods are labor-intensive and provide no 
visualization of the 3D structures. The need for methods that provide 3D information to 
study the bone has long been recognized. While methods such as serial sectioning and 
milling are valuable tools for understanding the structure of bone at the tissue level, these 
are destructive techniques that do not provide information at the cellular level and cannot 
be easily combined with other methods such as immunohistochemistry to characterize 
cellular processes27,28.   
CLARITY (Clear Lipid-exchanged Acrylamide-hybridized Rigid Imaging / 
Immunostaining / in situ-hybridization-compatible Tissue hYdrogel) was originally 
developed for soft tissues such as the brain4recently there has been a surge in optical 
clearing methods for a variety of applications, for example profiling of tumor biopsies and 
brain tissue 4,5,29-33. Bone is a more complex histological sample owing to its hard (mineral) 
and soft (bone marrow) tissue, and accordingly osseous tissue has remained a challenge, 
despite some promising developments reviewed in32,34. One method for investigating intact 
bones and their 3D microenvironments at sub-micron resolution is to render the tissue 
optically transparent. Bone transparency can be accomplished by coupling refractive index 
(RI) matching reagents with removal of minerals and lipids that scatter light. Most bone 
clearing literature is based on solvent clearing methods35-38 . These methods focus on RI 
matching and solvation of some lipids, but do not remove minerals32,34. In general, these 
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solvent-based clearing methods have achieved an imaging depth of approximately 200 µm 
using two-photon microscopy36. Murray’s clearing method was recently modified to clear 
bisected long bones and achieved an imaging depth of approximately 600 µm with confocal 
microscopy39. Despite these advances, manipulation and subsampling of the bone is 
required for deep imaging, thus disrupting the intact bone architecture. A key limitation of 
Murray’s clearing method and its variants is that they quench endogenous fluorescence, 
minimizing their application with transgenic fluorescent reporter lines, which are used to 
highlight key cell populations within the bone and marrow. Consequently, there is a need 
for a clearing method that maintains the intact bone structure, preserves endogenous 
fluorescence, and allows deeper imaging within intact bone without manipulation for sub-
sampling. 
In our prior work33 we noticed that decalcification (deCAL) of bones by EDTA could 
in principle expand CLARITY applications to osseous tissues but we only achieved modest 
optical access (200–300 µm). In this work we introduce deCAL CLARITY for bones, a 
specialized protocol that incorporates continuous convective flow during the clearing 
process, amino alcohol to minimize tissue autofluorescence40,41, and an imaging procedure 
that minimizes refractive index variations in light-sheet microscopy. These improvements 
allowed us to achieve whole-bone clearing with an imaging depth of up to approximately 1.5 
mm, while maintaining native tdTomato fluorescence and a signal-to-noise ratio (SNR) that 
permitted detection and 3D placement of single cells. We present a comprehensive platform 
based on whole bone clearing, light sheet imaging with a custom-built microscope, and 
dedicated computational methods for counting fluorescently labeled cells. We use this trio 
of methods to visualize and quantify the total number of osteoprogenitors contained within 
a volume of mouse bone and map their 3D spatial distribution in response to a sclerostin 
antibody (Scl-Ab), a bone-forming agent. 
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3.3 Results 
Bone CLARITY renders intact bones transparent while preserving endogenous 
fluorescence  
We developed and applied a bone clearing method to render the tibia, femur, and 
vertebral column of mice transparent for light-microscopy investigation (Fig. 1A). The key 
steps of the sample preparation including tissue clearing and autofluorescence removal are 
outlined in Fig. 1B and fig. S1. The bone is decalcified to increase light and molecular 
penetration through the tissue while leaving a framework of bone matrix with similar 
structural characteristics to dense fibrous connective tissue. DeCAL CLARITY employs 
an acrylamide hydrogel to support the tissue structure and minimize protein loss prior to 
the delipidation step.  The detergent sodium dodecyl sulfate (SDS) is used to remove lipids 
in order to minimize their light scattering effects. We observed high autofluorescence in 
the bone marrow, one of the primary sites of heme synthesis. As heme is strongly 
autofluorescent, in the final step of the process we used the amino alcohol N,N,N',N'-
tetrakis(2-hydroxypropyl)ethylenediamine40,41  to remove heme, which minimized marrow 
autofluorescence by  approximately 3-fold (fig. S2). All of the above clearing stages were 
conducted on a temperature controlled stir plate that provides continuous convective flow 
(fig. S3, auxiliary design file). This accelerates and improves the clearing process for entire 
organs compared with passive clearing33. The samples did not change size during the 
clearing process (fig S4).  
 The imaging of intact bone tissue using a point scanning method, for example 
using a confocal microscope, poses an operational challenge because acquisition times are 
prolonged, with concomitant photobleaching42,43 44. To address this, we built a custom 
light-sheet fluorescence microscope (LSFM) with confocal slit-detection (fig. S5)33 45. To 
modify the LSFM to image bones, an additional light-sheet path was added to illuminate 
the bones from two opposite directions. This additional light path improved optical access 
to areas containing a high percentage of cancellous bone, which typically scatter light more 
extensively and consequently lower the SNR. Given a particular depth scan, the sample is 
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illuminated by only one of the two light-sheet paths, whichever provides the better contrast. 
We use only one illumination path per depth scan because there is always one illumination 
direction that scatters less light and thus provides superior image quality. To minimize RI 
mismatch between the objective lens and the bones, the samples are directly immersed in 
the immersion chamber without the use of a quartz cuvette to hold the sample. If RI 
variations still persist, the position of the detection objective is changed for each tile and 
specific depth along the Z-scan to mitigate any resulting out-of-focus aberrations. The 
LSFM captures images at a frame rate of 22 frames per second (16-bit depth) and produces 
0.176 GB of imaging data per second. Large datasets are thus acquired for each imaged 
bone (50–500 GB). In order to manage these large datasets, we designed a computational 
pipeline that includes image stitching, automatic detection of individual cells, and volume 
of interest (VOI) rendering for analysis (Fig. 1C).  
To validate the protocol, we applied our clearing and imaging method to locate 
progenitor cells in the long bones and vertebrae of transgenic reporter mice. A Sox9CreER 
transgenic mouse line was used in which, upon tamoxifen injection, multipotent osteoblast 
and chondrocyte progenitor cells express tdTomato21,46. We visualized the endogenous 
fluorescence of Sox9+ cells using Bone CLARITY (Fig. 1D and E). Quantification of the 
imaging depth in different regions of the tibia, femur, and vertebral body showed that we 
were able to image through the diaphysis of the femur (movie S1) and tibia (movie S2) and 
the entire vertebral body (movie S3). Furthermore, we were able to reliably detect Sox9+ 
cells up to approximately 1.5 mm deep into the bones (fig. S6). Collectively, deCAL 
CLARITY coupled with LSFM and the data-processing pipeline is an effective clearing, 
imaging, and data processing protocol to investigate intact mouse bones. 
 
Semi-automated computational pipeline quantifies Sox9+ cells in mouse tibia 
and femur 
To demonstrate that biological environments can be observed and quantified with 
Bone CLARITY, we first counted Sox9+ cells in the tibia and femur. We found that Bone 
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CLARITY allows for detection and quantification of individual Sox9+ cells in 3D (Fig. 
2A), some of which appear associated with small vessels. Owing to the large VOI (Fig 2A, 
gray surface), we created a semi-automated cell-detection algorithm (Fig. 2B and fig. S7). 
The algorithm divides the 2D images that make up the Z-stack (or depth scan) into N small 
overlapping regions, and then adaptively thresholds the 2D images into binary images on 
the basis of the local mean and standard deviation of fluorescence. The resulting binary 2D 
images are further subject to morphological operations to eliminate noise and discontinuity 
within a cell. All of the 2D binary images are then combined into a 3D matrix. From the 
3D matrix, only volumes that fit the properties of a Sox9+ cell are maintained, thus avoiding 
erroneous counting of large blood vessels or small autofluorescence artifacts. All cells 
outside the user-defined VOI (Fig. 2A) are discarded. The cell candidate centroid locations 
are then imported to 3D visualization software for quality control. During the quality 
control stage, the annotator reviews the entire 3D volume and corrects the automatic results 
by marking false negative cells and omitting false positive cells. Therefore, at the end of 
the quality control stage, the cell counts are equivalent to cell counts that are performed 
manually. According to our experiments, a fully automatic pipeline only achieves on 
average 52% sensitivity and 36% precision. It should be noted that removing false positives 
is a faster operation in the 3D visualization software than adding false negatives, therefore 
the value of sensitivity outweighs the need for precision. 
 We quantified the number of fluorescently labeled Sox9 cells in the femur and tibia 
of Sox9CreER mice versus two control groups: Sox9CreER mice without tamoxifen 
administration and wild-type mice without the transgenes (Fig. 2C). The analyzed volume 
for each group was comparable (fig. S8). The cell counts in the Sox9CreER group without 
tamoxifen administration can be attributed to leakage of the reporter line because there was 
no visible expression of tdTomato in the wild-type control samples47.  Qualitatively, this 
leakage can be observed in fig. S9, where the expression of the tdTomato signal is 
compared between the experimental group and the two control groups. We next quantified 
the cell distribution as a function of distance from the periosteal surface along the 
longitudinal plane (schematic in Fig. 2D). Based on our analysis, most of the cells in the 
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diaphysis reside adjacent to the endocortical surface, with mean distances from the 
periosteal surface of approximately 136.9 µm and 143.6 µm for the tibia and femur, 
respectively (Fig. 2E). This result supports similar findings in48 and validates deCAL 
CLARITY as a reliable method to resolve and quantify individual cells in intact bone and 
marrow spaces. It should be noted that Bone CLARITY is not limited to visualize cell 
populations in transgenic animals only and that antibody staining is also feasible (fig. S10).  
However, for maximum penetration of the antibody into the bone, it is recommended to 
bisect the bone prior to the clearing process.   
 
Bone clearing can complement section-based stereology 
 Design-based stereology is the gold standard method to quantify total cell numbers 
and densities in organs while preserving spatial information49. Stereology relies on 
statistical sampling methods. Systematic uniform random sampling (SURS) is a frequently 
used sampling method that efficiently reduces the variance of the estimate compared with 
random sampling. SURS obtains histological sections from an organ to reduce the amount 
of tissue for analysis. SURS samples at regular uniform intervals with the first sample 
collected at a position random within the first interval50,51. The number of cells in a tissue 
volume is a zero-dimensional geometric feature, and to avoid bias based on the cell size or 
shape, a probe based on two thin physical sections or optical planes separated by a known 
distance (disector), is used to accomplish quantification52 53.  Cells are typically counted in 
a known fraction of the organ, which allows for an estimation of the total number of cells 
in the entire organ54. The spatial distribution of cells can also be obtained using second-
order stereological methods55.    
Applying stereological methods to cleared organs offers notable time-saving 
because clearing precludes the need for labor-intensive sectioning. Using the Bone 
CLARITY method and our 3D counting scheme, we investigated the variability in 
stereology estimates as a function of the number of slices for both SURS and simple 
random sampling in stereology experiment simulations. Figure 3A shows one 
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representative selection of N random uniformly spaced sections for a simulated SURS 
experiment in the femur, tibia, and vertebral body. Fig. 3B shows the estimates for the cell 
count of an entire VOI based on N sampled slices, and Fig. 3C illustrates the coefficient of 
variation of simulated stereology experiments that were conducted with N slices. To 
estimate the coefficient of variation for each N representative slices, 5 simulated stereology 
experiments were conducted. In these simulations, as expected, variance decreased rapidly 
with increasing number of slices for femur, tibia, and vertebrae. Precision of the 
stereological estimate would likely be improved with proportionator sampling, a form of 
non-uniform sampling better suited to rare structures56. Therefore, the 3D counting method 
offers several advantages for quantifying rare cellular populations: the ability to detect 
subtle changes that might be overlooked because of sampling variance, elimination of the 
need for sectioning, and 3D visualization.  
 
Sclerostin antibody increases the number of Sox9+ cells in the vertebral column 
We next applied deCAL CLARITY to the vertebral column, a bone that is highly 
susceptible to fractures due to osteoporosis57 and whose complex geometry is particularly 
difficult to probe with traditional sectioning-based methods. We cleared and imaged the 
vertebrae from mice, and focused on the 4th lumbar vertebral body (L4), which is dense, 
opaque, and predominately composed of cancellous bone. Fig. 4, A and B show schematics 
of lateral and transverse cuts from a representative vertebra. Fig. 4B also shows the 
approximate locations (dashed lines) of the digital sections (30 µm thickness) that are 
shown in Fig. 4C. The lateral processes that extrude from the vertebral body can be seen 
in the horizontal edges of the 650 µm section. These processes were excluded from the cell 
counts, as illustrated by the representative VOI (Fig. 4D). Additionally, careful attention 
was given to ensure the exclusion of the intervertebral discs and cartilage endplates from 
the VOI, as they are both primarily populated by chondrocytes. These chondrocytes 
express Sox9 and are tdTomato+ after tamoxifen administration, and thus require careful 
exclusion for accurate cell counts of fluorescently marked osteoprogenitors. The 
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quantification of vertebral Sox9-tdTomato cells after tamoxifen administration versus the 
two control groups, Sox9CreER mice without tamoxifen administration and wild-type 
mice, can be seen in Fig. 4E. Again, we observed that the Sox9CreER transgenic animals 
without tamoxifen administration display mild leakage of tdTomato expression (Fig. 4E 
and fig. S9). Overall, similar to the cell distribution results presented for the tibia and 
femur, the Sox9+ cells were primarily located adjacent to the endocortical surface (Fig. 4, 
F and G), with a mean distance of 138.8 µm and 137.6 µm for the tamoxifen-negative 
(Tam.-) and tamoxifen-positive (Tam.+) groups, respectively.  
We next tested the effects of sclerostin antibody (Scl-Ab) on the total number of 
Sox9+ cells in the vertebral column. Sclerostin is an extracellular inhibitor of the canonical 
Wnt signaling pathway and is highly expressed in osteocytes. Inhibition of sclerostin leads 
to activation of canonical Wnt signaling in the osteoblast lineage resulting in a rapid but 
transient marked increase in osteoblast number and bone formation58. Although the early 
dramatic increase in osteoblast number is considered to be at least in part due to activation 
of bone lining cells59, the contribution of osteoprogenitors to this early increase in 
osteoblast number is unclear.  While a decrease in osteoprogenitors has been demonstrated 
to be associated with the attenuation of bone formation that occurs with long-term Scl-Ab 
treatment in rats, stereological methods have not detected effects on progenitor number 
coincident with the maximal increase in osteoblast number. In order to gain insight into the 
acute effects of Scl-Ab on osteoprogenitors, we conducted an experiment as outlined in 
Fig. 4H. On day one, Sox9CreER mice were injected with Scl-Ab (100 mg/kg 
subcutaneously). Four days afterwards, we provided a second dose of Scl-Ab along with 
tamoxifen to label Sox9+ cells with tdTomato. We euthanized the animals five days later 
and cleared the bones using Bone CLARITY. Indeed, after performing blinded 
quantification of Sox9+ cells, we observed an increase in the total number of Sox9+ cells in 
the vertebral body nine days after initial Scl-Ab treatment versus the vehicle control group 
(Fig. 4I). We did not observe any significant changes to the vertebra body volume (Fig. 4J) 
between the experimental and control groups at this early time point. These results 
demonstrate that there is an increase in osteoprogenitors that are likely recruited to the bone 
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surface to contribute to the increase in osteoblast number. The distribution of cells as a 
function of distance from the surface can be seen in Fig. 4K, with mean distances of 
approximately 99.9 µm and 137.8 µm for the vehicle and treated groups, respectively.  
3.4 Discussion 
In the bone remodeling process, bone health is maintained through continuous 
cycles of bone resorption by osteoclasts and bone formation by osteoblasts. Imbalances in 
these physiological processes can lead to various bone diseases such as osteoporosis, which 
affect millions of people in the United States alone57,60. In order to gain better insight into 
potentially effective treatments for osteoporosis, it is imperative to study the physiological 
processes that occur in healthy and diseased bone and understand the molecular and cellular 
mechanisms within the 3D microenvironment. We demonstrate that the Bone CLARITY 
technique renders the tibias, femurs, and vertebral bodies of mice optically transparent 
while preserving bone morphology and an endogenous fluorescent reporter signal. In 
addition to matching the RI of the tissue, Bone CLARITY also removes minerals and 
lipids, thus enabling us to reconstruct a whole vertebral body as well as the entire diaphysis 
from the tibia and femur.  
For maximum impact, clearing and imaging platforms need to be easy to use and 
scalable. The trio of methods presented here has a few limitations in its current rendering 
that could be improved in the future, such as the addition of antibody staining to the 
clearing workflow, reducing processing time and overcoming the technical barriers of 
acquiring and analyzing big datasets. Antibody staining of an intact bone is challenging 
owing to poor penetration by relatively large intact antibodies. In order to improve antibody 
penetration, we bisected and cleared half of a tibia and femur. In the bisected and cleared 
bones, the antibody penetrated up to 400 µm from the bone surface and showed high 
specificity and SNR (fig. S10).  The use of small-molecule staining methods (e.g. single-
molecule hybridization chain reaction61 could allow the labeling of intact bones while 
achieving reliable staining depths. Meanwhile the ability to retain and detect endogenous 
fluorescence has proven highly enabling although the gentle clearing reagents used in 
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deCal CLARITY do introduce a compromise in processing time (28 days). Utilizing faster 
decalcification agents, such as formic acid, might shorten the current decalcification time 
of 14 days albeit the fluorescent proteins generated by the reporter genes used in this study 
might lose their fluorescence under acidic conditions42,62. Delipidation is also a lengthy 
stage in Bone CLARITY but necessary to reduce scattering from lipids present not only in 
the mineralized bone tissue, but highly abundant within the bone marrow. Consequently, 
delipidation ensures high-quality optical access deep in the bone. Although the use of 
customized microscopy and software might not be easy to implement in a non-technical 
setting, commercial LSFM systems with a streamlined user interface and associated 
software are rapidly evolving to support the types of application described here. For data 
processing, we found that fully automated cell-detection algorithms were difficult to apply 
within cleared tissue. SNR variations arising from non-uniform illumination and 
fluorescence detection within the bone resulted in unsatisfactory precision, necessitating 
manual quality control. The simple automated tools that we developed are fast and adaptive 
and in general are able to save annotator time while improving precision and reducing 
error; however, more work is required to achieve a reliable, fully automated algorithm for 
cell counting. In general, data handling, visualization, and analysis would benefit from 
individual developers sharing their code in an open-source environment, which would 
allow the scientific and medical community to efficiently customize software relevant for 
the application at hand.   
Bone CLARITY enables clearing of mouse bones while retaining the integrity of 
the bone marrow and endogenous fluorescence. Following clearing, we achieved 3D 
reconstructions of a vertebral body and long bone diaphyses, and attained an imaging depth 
of approximately 1.5 mm for the epiphysis of long bones. Using a computational pipeline 
to process large datasets and detect single cells in bone, we mapped the spatial distribution 
of osteoprogenitor cells. Additionally, we demonstrated the advantages of 3D methods in 
estimating rare cell populations that are not readily amenable to sampling by traditional 
stereology methods. It should be noted that combining traditional stereology methods with 
tissue clearing techniques can be advantageous, especially in cases where quantification of 
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complicated structural elements cannot be done automatically. Therefore, subsampling is 
advantageous for manual quantification within a reasonable timeframe. Finally, to further 
demonstrate the utility of our clearing method, we treated a cohort of adult reporter mice 
with a sclerostin antibody, a bone-forming agent, for 9 days. Previous stereological studies 
in rats treated with Scl-Ab for 8 days revealed a dramatic increase in total osteoblast 
number in the vertebrae coincident with increased bone formation, but no significant effect 
on bone progenitor numbers58. We found that, after 9 days of treatment in mice, the total 
number of osteoblast progenitor cells increased by 36% compared with the control group. 
This result was not surprising based on the literature58, but it has been challenging to 
demonstrate using stereological methods given the rarity of osteoprogenitor cells, 
particularly in the vertebrae. This underscores the greater sensitivity of our clearing, 
imaging, and data-processing protocol for quantifying rare cell populations as well as using 
lineage tracing to mark progenitors, as opposed to immunophenotyping in tissue sections.  
Overall, continued developments in tissue clearing 6,32,34, imaging, and data analysis can 
facilitate translational research that will provide insight into the efficacy and safety of new 
bone-modulating drugs by profiling their effects on progenitor cell populations.  
Other fields might also benefit from applying the bone clearing technique, such as 
neuroscience. Removal of the skull damages the interface between the skull and the 
underlying vascular bed and neuronal tissue. Preservation of this interface would be 
beneficial for studying the lymphatic vessels residing within it, assessing head trauma (e.g. 
percussive injuries), and characterizing the positioning of head-mounted brain implants in an 
intact environment9,63.  
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3.5 Main figures 
 
Fig. 1. Bone CLARITY renders intact bones transparent while preserving endogenous 
fluorescence. (A) Micrographs of mouse tibia, femur, and vertebral column before and after 
CLARITY. Bones were rendered transparent using deCAL CLARITY. (B) Block diagram 
outlining of the key steps of Bone CLARITY sample preparation. The procedure includes: 
demineralization, hydrogel stabilization, lipid removal via constant flow, and 
autofluorescence removal. (C) A schematic diagram of the imaging and computational 
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pipeline that utilizes the interface between 3D visualization and image-processing programs. 
(D) Maximum intensity projection (MIP) fluorescent image of the tibia and zoomed in digital 
slices (red = Sox9 and green = autofluorescence). Using Bone CLARITY, bones were 
imaged from one end to the other in the diaphysis (magnified images) and approximately 1.5 
mm deep into the epiphysis (movies S1-3). Dotted yellow and blue boxed regions in the MIP 
represent the area of zoom in the digital slices (30 µm thick). The purple and red dotted boxed 
regions in the digital sections represent the area that is shown with further higher 
magnification. The white dotted lines represent the boundaries of the compact bone. (E) MIP 
fluorescent image of the vertebral body. 
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Fig. 2. Bone CLARITY enables quantification of fluorescently labeled Sox9+ cells in the 
mouse tibia and femur. (A) Femur MIP fluorescent image and magnified images showing 
single Sox9+ cells in the vicinity of the third trochanter (red = Sox9 and green = 
autofluorescence). The gray surface surrounding the femur represents an overlay of the 
volume of interest (VOI); only the cells that reside within the VOI are quantified. The purple, 
blue and yellow boxed regions in the MIP represent progressive magnification. (B) Block 
diagram of the semi-automated cell detection pipeline where cell candidates are identified 
via adaptive thresholding and their volume calculated. A predetermined selection criterion 
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based on cell volume is used to reject blood vessels or any detected blobs that are too large 
or too small. (C). A comparison of fluorescently labeled Sox9+ cell numbers between the 
experimental: tamoxifen positive (Tam+) and control groups: wild-type (WT) and tamoxifen 
negative (Tam-) for the femur and tibia; n = 3 animals per group; 1 bone per animal. For tibia, 
WT versus Sox9+;Tam.-, P = 0.0002 and Sox9+;Tam.- versus Sox9+;Tam.+, P = 0.0008. For 
femur, WT versus Sox9+;Tam.-, P = 0.012 and Sox9+;Tam.- versus Sox9+;Tam.+, P = 0.002. 
All values are mean  ± s.e.m; two-tailed, unpaired t-test. (D) Schematic illustrating how the 
distance of Sox9+ cells from the surface is calculated. (E) The distribution of the number of 
Sox9+ cells versus the distance from the bone surface.  
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Fig. 3. Using intact tissue clearing methods reduces cell estimate variability compared 
with traditional tissue sectioning methods. (A)  Schematic diagram showing the sample 
selection procedure for systematic uniform random sampling (SURS) of the mouse femur, 
tibia, and vertebral body. N uniformly spaced 2D sections are selected, offset by a random 
starting distance. The red single arrow indicates the random starting point, while the double 
arrow indicates the distance between the 2D sections. (B) Sox9+ cell number estimation as a 
function of the number of sampled sections in a representative simulated stereology 
experiment using both SURS (red dots) and simple random sampling (blue dots). To simulate 
a stereology experiment, the cell density in the sampled sections is used to interpolate the 
cell number in the entire VOI. The black dashed line represents the ground truth, cell number 
based on the entire volume. (C) The coefficient of variation of five simulated stereology cell 
number estimates as a function of the number of sampled slices using SURS (red dots) and 
simple random sampling (blue dots).  
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Fig. 4. Bone CLARITY enables quantification of the effect of sclerostin antibody on the 
number of fluorescently labeled Sox9 cells in the mouse vertebra. (A) Schematic 
depicting the lateral view of a mouse vertebra. The intervertebral disk is labeled in red; 
chondrocytes proliferate there after differentiation from tdTomato-Sox9+ cells (chased for 7 
days). The marrow is represented in light orange. (B) Transverse view of an L4 vertebra. The 
cell counts are isolated to the vertebral body, and the dashed lines approximate the locations 
of the sections shown in C.  (C) Digital sections (30 m thick) at different depths along the 
vertebral body (Z = 200 m and 650 m), red = Sox9 and  green = autofluorescence. The 
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intervertebral disks are notable at the vertical boundaries of the images. The white arrows in 
the color-coded magnified images point to Sox9+ cells, and the dashed white line in the 
magnified image marks the interface between the compact bone and the marrow. (D) 
Micrograph of the mouse vertebral body showing a representative VOI (gray surface), which 
does not include the intervertebral disks. (E) Total cell number in tamoxifen-injected mice 
versus control groups. For WT versus Sox9+;Tam.-, p = 0.0311 and Sox9+;Tam.- versus 
Sox9+;Tam+, p = 0.0002. (F) Schematic illustrating how cell distance from surface is 
determined on a transparent vertebral body VOI. For each cell, the distance is defined as the 
shortest path to the surface in any direction. (G) The distribution of Sox9+ cells as a function 
of distance from the endocortical surface. (H) Schematic of the sclerostin antibody (Scl-Ab) 
experimental timeline. (I) Quantification of the number of cells within the VOI outlined in 
(D) in the Scl-Ab and vehicle treated mice. For Sox9+;Tam.+;Scl-Ab- versus 
Sox9+;Tam.+;Scl-Ab+, p = 0.0183. (J) No significant change in the vertebral body volume 
was observed between the Scl-Ab group and the vehicle group. For Sox9+;Tam.+;Scl-Ab- 
versus Sox9+;Tam.+;Scl-Ab+, p = 0.3403.  (K) The distribution of Sox9+ cells as a function 
of distance from the endocortical surface. All values are mean  ± s.e.m; two-tailed, unpaired 
t-test. 
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3.6 Supplementary Figures 
 
Fig. S1. Bone CLARITY clearing process. (A) As a first step (blue) in Bone CLARITY 
method transcardial perfusion is performed with 0.01M PBS, pH 7.4, and 4% 
paraformaldehyde (PFA) in PBS, pH 7.4. Hard tissue is then extracted and post-fixed with 
4% PFA in PBS, pH 7.4 at 4°C for 16 hours. Hard tissue is then decalcified (orange). During 
this step, daily-exchange of 10% EDTA in PBS, pH 8, at 4°C under constant stirring is 
performed. Hydrogel stabilization to prevent protein loss is carried out (purple). The tissue 
is incubated in a hydrogel composed of 4% acrylamide with 0.25% VA044 in PBS at 4°C 
under constant stirring for 16 hours. Afterwards, the hydrogel is degased with nitrogen gas 
and polymerized at 37°C. Delipidation is carried out with 8% SDS in PBS, pH 7.4 at 37°C 
under constant stirring (green). A wash step with PBS is performed before heme removal 
from the tissue (gray). Heme removal is performed with 25% amino alcohol in PBS, pH 9, 
at 37°C under constant stirring (red). A second wash step is performed on the tissue (gray). 
Finally, the tissue is refractive index matched to 1.47 through daily step-wise buffer exchange 
(pink).   
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Fig. S2. The effect of amino alcohol on reducing autofluorescence. (A) MIP of a mouse 
femur rendered transparent using Bone CLARITY without the addition of amino alcohol. 
The dashed regions show the locations of progressively zoomed in images. (B) MIP of the 
same mouse femur shown in (A), after the addition of amino alcohol. Zoomed in images of 
the same regions as in (A) show that the same spatial pattern in the sample was maintained 
after amino alcohol treatment. (C) A representative image of the regions of tissue (marrow 
and compact bone) used for the analysis of the autofluorescence quenching effect. (D) The 
mean ratio of marrow to compact bone intensity in a mouse femur and tibia before and after 
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the addition of amino alcohol - which removes autofluorescence in the bone marrow. The 
intensity ratio between the marrow and compact bone should be independent of the imaging 
depth and illumination variations. (E) The ratio of marrow to compact bone intensity from 
different sample regions along the imaging depth of the bone. A depth of 0 μm refers to the 
first region along the imaging depth that had both marrow and compact bone. 
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Fig. S3. Bone CLARITY setup. (A) The individual parts of the setup, which is composed 
of: (1) A 3D printed holder for histology cassettes. (2) A large histology cassette with rubber 
inserts. (3) Rubber inserts to prop the tissue above the 3D printed holder, and consequently 
position the tissue within the convective current. (4) A stir bar. (5) A glass slide for placement 
of the stir bar above the 3D printed holder. (B) The histology cassettes arranged inside a 15 
cm petri dish with a 14.7 cm plastic petri dish cover. (C) The petri dish is placed on a closed 
loop temperature controlled stir plate. For repeatability, six cassettes are always placed in the 
chamber, and the stir bar is rotated at a speed of 400 rotations per minute at 37ºC. The design 
file for the 3D printed holder is available as an auxiliary supplementary file.  
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Fig. S4. Sample progression through Bone CLARITY clearing process. (A) Micrographs 
documenting the progression of the femur, tibia and vertebral column throughout each phase 
of Bone CLARITY. (B) The percent change in length of the bones before and after Bone 
CLARITY.  (C) The percent change in width of the bones before and after Bone CLARITY. 
For (B) and (C), n = 6 for the femur, n = 5 for the tibia and n = 4 for the vertebral column. 
All values are mean ± s.e.m. 
  
39 
 
 
 
Fig. S5. LSFM set-up. (A) Schematic diagram of the multi-color dual-side illumination 
light-sheet microscope with the confocal slit detection. The microscope acquisition speed is 
up to 22 frames per second; consequently, it allows for high-resolution acquisition of large 
cleared tissue. L – lens, M – mirror, DM - dichroic mirror, GS – galvano scanner, BS – beam 
splitter, MS – mechanical shutter, RL – relay lenses and EF emission filter. (B) A photograph 
of the light-sheet setup, the sample (S) is directly immersed in the sample chamber (SC).   
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Fig. S6. Signal quality metrics to quantify imaging depth of Bone CLARITY. (A) MIP of 
a cleared mouse femur with estimates of imaging depth limit at different anatomical regions. The 
arrows indicate the direction of analysis and the calculated imaging depth. (B) Examples of 
isolated Sox9+ cells at different imaging depths and in different bone regions. Sox9+ cells remain 
distinguishable at the deepest parts of the metaphysis and diaphysis, but signal loss is evident in 
the deeper parts of the epiphysis. The same analysis was repeated for a cleared mouse tibia (C) 
and vertebra (D). (E) The peak signal-to-noise ratio (PSNR) of isolated Sox9+ cells. The dashed 
lines represent a qualitative estimate of where cells are no longer distinguishable from 
background noise, at a PSNR of around 24. 
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Fig. S7. Computational pipeline. (A) A block diagram of the computational pipeline. (B) 
VOI creation in the vertebra body. In each block of approximately 10 longitudinal sections 
a ROI (dotted line) is marked around regions that contain marrow. The VOI is then 
interpolated from the ROIs. (C) VOI creation in the tibia and femur, where approximately 
10 transverse slices are used to create the VOI. For cell distance to surface calculation, the 
VOI is extended from both ends, in order to ensure distance calculation to the real bone 
boundaries and not to artificial perpendicular surfaces.   
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Fig. S8. Volume comparisons in the tibia and femur.  No significant change in the volume 
of interest was observed between the Sox9+ and Tam+ group and the two control groups (wild 
type; Sox9+ and Tam-). For all groups n = 3, all values are mean ± s.e.m; two-tailed, unpaired 
t-test, (p ≥ 0.05 = N.S.).   
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Fig. S9. TdTomato expression in the vertebral columns. (A) No fluorescence signal is 
present in the emission spectrum of tdTomato (556 nm laser excitation) in the vertebral 
column of a wild-type mouse. (B) Using the same imaging settings as in panel (A), Sox9+ 
mouse shows tdTomato expression even without tamoxifen induction. The fluorescence 
signal is primarily located at the endplates and attributed to leakage. (C) Using the same 
imaging settings as panel (A), Sox9+ mouse shows high levels of tdTomato expression after 
tamoxifen induction.   
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Fig. S10. Antibody staining using Bone CLARITY. (A) The approximate region imaged 
in the bisected femur is outlined by a black square. Digital slices of 10 µm thickness are 
shown in 300 and 400 µm from the surface of the femur. Red shows Osteocalcin staining of 
cells lining the surface of bone, green shows autofluorescence. (B) The region imaged in the 
bisected tibia is outlined by a black square. Digital slices of 10 µm thickness are shown in 
200 and 300 µm from the surface of the tibia. Red shows Osteocalcin staining of cells lining 
the surface of bone, green shows autofluorescence. 
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3.7 Supplementary movie captions 
Movie S1: Visualizing endogenous fluorescence throughout a cleared mouse femur.  
The movie shows a MIP image of an entire mouse femur at different angles and zoomed in 
view of the greater trochanter area. Digital sections with 30 µm thickness are shown at 
different bone depths at the greater trochanter. Sox9+ cells are labeled with red fluorescent 
protein (tdTomato), while tissue autofluorescence in green provides structural cues. 
(doi:10.22002/D1.234)1 
Movie S2: Visualizing endogenous fluorescence throughout a cleared mouse tibia. MIP 
image of an entire mouse tibia rotated in different angles. Zoomed in digital sections (30 µm 
thick) of the tuberosity and the diaphysis are shown. The Sox9+ cells are labeled with 
tdTomato and tissue autofluorescence in green for structural orientation. When the red 
channel is turned off (Z = 2016 µm) some cellular processes can be seen. (doi: 
10.22002/D1.235) 1 
 
Movie S3: Visualizing endogenous fluorescence throughout a cleared mouse vertebral 
body. The movie shows an L4 vertebra body of a mouse. The intervertebral disks labeled in 
red can be seen in the vertical edge of the image. Longitudinal sections (30 µm thick) of the 
vertebra body at different depths can also be seen where the red channel shows Sox9+ cells 
and the green channel shows tissue autofluorescence. (doi: 10.22002/D1.236) 1 
 
 
 
 
1 = data file is stored at data.caltech.edu   
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3.8 Materials and methods 
Study design: The objective of this study was to enable the visualization and 
quantification of cell population in an intact bone tissue by developing and integrating 
tissue clearing, fluorescence microscopy, and a computation pipeline. Experimental and 
control animal cohorts were chosen based on preliminary data that suggested a large effect 
size. All transgenic animals used in this study are as described in the animals section. All 
wild-type animals used in this study were C57BL/6. To characterize the density of sox9+ 
cells and distribution within the femur, tibia and vertebral column, male transgenic animals 
of 6-7 weeks of age received a 2 mg tamoxifen IP on day 1 of the experiment to enable 
expression of a native fluorescent gene for 7 days before culling. For the study of the effects 
of sclerostin-antibody on total number of osteoprogenitor cells, a cohort of 7 weeks old 
male transgenic animals were treated with a sclerostin antibody at 100 mg/kg IP on day 1, 
and again 4 days later at 100 mg/kg IP with tamoxifen induction at 2 mg IP before culling 
on day 9 of the study. The sclerostin antibody was provided by Amgen.  During cell 
counting all manual quantification is performed in a blind manner to eliminate observer 
bias. Animals were randomly assigned to groups for experiments. Raw data values for cell 
counts are reported in an auxiliary supplementary file. 
Animals: A transgenic Sox9-creERT2 mouse (RIKEN BioResource Center, # 
RBRC05522) was crossed to a Rosa26-loxP-stop-loxP-tdTomato (R26R-tomato, 
JAX7914) reporter mouse to generate Sox9-CreERT2-R26-tdt. Sox9-creERT2-R26-tdt 
mice ages 6-7 weeks old were used in the experiments involved in labeling Sox9 cells (n = 
18). The labeling was achieved by the injection of 2 mg tamoxifen IP, which was dissolved 
first in 100% ethanol then in sunflower seed oil (Sigma, #S5007) overnight at 60oC. Mice 
were genotyped by PCR. All mice were analyzed in mixed backgrounds. Mice were group 
housed in sterile, ventilated micro-isolator cages on corn cob bedding in an AAALAC 
accredited facility. All procedures were conducted in compliance with the Guidelines for 
the Care and Use of Laboratory Animals approved by Massachusetts General Hospital’s 
Institutional Animal Care and Use Committee (IACUC). Animals were provided ad libitum 
access to pelleted feed (LabDiet 5010) and water (Standard drinking water of Boston, 
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Massachusetts, pH 7.8) via HYDROPAC. Animals were maintained on a 12:12 hour 
light:dark cycle in rooms at 64-79 F with 30-70% humidity under pathogen-free conditions.  
Bone deCAL CLARITY protocol: The clearing process is summarized in fig. S1. 
After euthanization, mice were perfused transcardially with 0.01M PBS (Sigma, #P3813) 
followed by 4% paraformaldehyde (PFA)  (VWR, #100496-496) and the femurs, tibias and 
L3-5 vertebral columns were extracted. The bones were post-fixed overnight in 4% PFA. 
To enhance clearing of hard-tissue, the demineralization phase was extended to 2 weeks 
with 10 % EDTA (Lonza, # 51234) in 0.01M PBS, pH 8. During the demineralization 
phase, samples were kept under constant stirring in histology cassettes (Electron 
Microscopy Sciences, #70077-W) at 4°C with fresh EDTA buffer exchanges daily. Next, 
the decalcified bones were embedded in a hydrogel matrix (A4P0) which consist of 4% 
acrylamide  (Bio-Rad, #1610140), 0% paraformaldehyde, and 0.25% thermo-initiator 
A4P0 (Wako Chemicals, VA-044)  in 0.01M PBS overnight at 4°C. The samples were 
degassed through nitrogen gas exchange for 5 minutes and polymerized at 37°C for 3 hours. 
After structural reinforcement with the A4P0 hydrogel, delipidation was carried out with 
8% SDS in 0.01M PBS, pH 7.4, for 4 or 5 days (vertebral body and long bones respectively) 
at 37°C under constant stirring (fig. S3). The samples were then washed for 48 hours in 
0.01M PBS with 3 buffer replacements. The amino alcohol N,N,N',N'-tetrakis(2-
hydroxypropyl)ethylenediamine (Sigma, #122262-1L) was added at 25% W/V in 0.01M 
PBS, pH 9, for 2 days at 37 °C under constant stirring for the purpose of decolorization of 
the tissue through heme group removal. Lastly, the bones were washed with 0.01M PBS 
for 24 hours and subsequently immersed in refractive index matching solution (RIMS). 
The bones were gradually immersed in RIMS (15) with a refractive index of 1.47 through 
daily step-wise RIMS exchange starting with RIMS 1.38, RIMS 1.43 and finally RIMS 
1.47.  
Light-sheet microscopy imaging: Prior to imaging, the sample was placed in the 
LSFM sealed immersion chamber for at least three hours, allowing the RIMS solution in 
the chamber to equilibrate with the residue RIMS in the bone sample. To minimize optical 
aberrations, the refractive index of the RIMS solution was measured and the correction 
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collar on the objective lens (10× CLARITY Objective lens with numerical aperture of 0.6, 
Olympus XLPLN10XSVMP) was set accordingly. To image the entire bone, multiple tiles 
with 10% overlap were acquired. Typically, the femur, tibia and vertebral body required 
13×5, 11×5 and 3×2 tiles respectively (vertical × horizontal). In a calibration stage that 
took place prior to the scan, the following parameters were defined for each tile: (i) Light-
sheet illumination direction; the LSFM has two light-sheets that illuminate the sample from 
opposite directions. Selecting the preferable illumination direction dramatically reduced 
scattering.  (ii) The start and end point of the Z-stack; this step was done in order to 
minimize the number of acquired images in an already big data set (50-500 GB). (iii) The 
focus points of the detection objective along the scan were defined to mitigate RI variations 
along the scan that created out-of-focus aberrations. Once the calibration stage was 
completed, the bone was imaged with a frame rate of 22 frames per second, and bit depth 
of 16 bits. The acquired data set size depends on the sampled voxel size. For a voxel size 
of 0.585×0.585×2 µm3 the tibia and femur produced ~ 250 GB of data per color channel, 
while the vertebral body produced ~ 30 GB of data per color. Generally, the datasets are 
down-sampled after acquisition for processing; the typical voxel sizes are 1.17×1.17×2 
µm3 and 2.34×2.34×2 µm3 for the vertebra column and long bones respectively.  
All experimental and control groups were imaged with the same laser power. For 
images that were acquired deep in the bone and when the SNR changed within the distance 
from the bone boundary, the contrast and gamma were adjusted in the displayed images. 
The gamma adjustment was done to visualize cells that exhibit both low and high intensity 
within the same field-of-view. Images from the vertebra (Sox9+ and Tam+ group) are 
representative of 13 vertebrae from 13 mice. Images from the tibia and femur (Sox9+ and 
Tam+ group) are representative of 5 tibias and 5 femurs from 5 mice.  
Statistical analysis: All statistical analysis was performed using GraphPad Prism 
version 7.01. For figures 2C, 4E, 4I and 4J, mean values for each group were compared 
using an unpaired t-test. In all graphs, data points per individual animal trial with the mean 
value and s.e.m are shown.  
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3.9 Supplementary methods 
Computational pipeline: LSFM generates multidimensional datasets on the order of 
hundreds of gigabytes, for example 500 GB for tibia with 2 color channels, motivating a 
necessity for high-throughput automated computational tools to do data processing, 
management, and visualization. Thus, we established a computational pipeline optimized for 
large datasets that interfaces between 3D visualization and analysis software (Imaris, 
Bitplane) and a programming framework (Matlab, Mathworks) although alternatives can 
also be used (e.g. Amira, Python).  
Tile stitching was done with TeraStitcher. The acquired tiles (.tiff format) were saved 
according to the TeraStitcher two-level hierarchy and file naming convention. The resulting 
stitched tiles were saved as large individual.tiff format file per Z section. To accelerate 
processing and manipulation of 3D images in Imaris, the lateral resolution was down-
sampled by a factor of 2 and 4 for vertebrae and long bones, respectively. These image stacks 
were then converted into a single large multiresolution 3D Imaris image. The 3D image is 
then used to construct the VOI, performing quality control for the automatic cell detector, 
and obtaining relevant statistics about the position of the cells within the VOI.  
Using Imaris surface tools, a VOI was constructed around the bone surface, while 
excluding connective tissue. The VOI was used to count cells and evaluate morphology (fig. 
S7). For the femur and tibia, the VOI was defined around known anatomical regions: the 
third trochanter and tibial crest, respectively. The surface for the vertebral body aimed to 
surround the inner marrow of interest and exclude surrounding compact bone and 
chondrocyte-dense endplates.  
2D stitched images were used for automatic Sox9+ cell detection (Fig. 2B). The 
algorithm iterates through the image stack and divides the 2D stitched images into a number 
of smaller regions. For each region, the standard deviation and mean value of fluorescence 
intensity is calculated. Sox9+ cells are expected to be significantly brighter in intensity than 
the surrounding tissue, therefore each sub region is thresholded with a value of approximately 
9 standard deviations above the mean value. The thresholded images are then converted to a 
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binary format and morphological operations are conducted to improve connectivity and 
discard noise. A 3D binary matrix is then constructed from the 2D binary images and 
connected voxels are grouped into 3D blobs. Blobs that showed one of the following criteria 
were removed: (i) blobs with volume outside of a 523-33,500 µm3 range, (ii) blob with spatial 
position outside of the VOI and (iii) blobs that show strong signal in the autofluorescence 
channel. The centroids of the remaining blobs are imported into Imaris to perform manual 
adjustments. The goal of the automatic detection is to facilitate manual detection by saving 
time and reducing the chance of error from long annotation sessions.  
Using Imaris’ clipping plane tool, the 3D image is divided into thick slices (~ 100 
µm) to allow for manual adjustments of the automatically detected cells. Viewing cells in 
these thick sections allows for visualization of 3D features that help to accurately identify 
cells. When counting the cells, 2 color channels were used to disambiguate between 
autofluorescence (green) and the true Sox9+ signal (red). If the Sox9+ cell under question is 
present with strong intensity in the autofluorescence channel, then it was not included in the 
quantification. 
Following manual cell count adjustments, Imaris was used to generate distance to 
surface and cell count statistics. The surface was imported into Imaris’ cell object with the 
marked Sox9+ spots as its vesicles. Automatically generated statistics were imported to 
Matlab for further processing and plotting. 
Sample mounting for light-sheet microscope: To mount the sample for LSFM, one 
end of a 4 cm long plastic capillary was flattened using a plier, and a small amount of All 
Purpose Krazy Glue (KG585) was applied on this end. The flattened end was later placed on 
the edge of the cleared condyles (femur) and L3 (vertebral column) bone while moderate 
pressure was applied. Four minutes later, the capillary bonded with the bone and the sample 
was placed back into RIMS. Before imaging, the plastic capillary was fitted to a glass 
capillary, which can be attached to the sample stage of the LSFM (fig. S5). 
Simulated stereology: To investigate the variability between 3D counting and 2D 
section counting, we performed a series of simulated stereology experiments using our 3D 
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datasets. To start, the coordinates of each cell center were imported to MATLAB as a list, 
and the VOI was imported to MATLAB as a binary mask. From the binary mask, the volume 
of each 2D section was calculated by accumulating the number of pixels in the 2D section 
and multiplying it by the voxel size. Then, a simple random sampling stereology experiment 
was simulated by stochastically selecting N digital sections (6 μm thick) from the entire VOI. 
Only cells whose centroids were within the volume of the selected digital sections were 
counted, this guarantees that each cell will be counted only once and cell will not be 
overrepresented. To calculate the cell density, the total number of counted cells in the 
selected digital sections was divided by their accumulated volume. From sampled cell 
density and the known volume of the entire bone, the total number of cells in the bone was 
estimated. In order to calculate the coefficient of variation, each experiment was repeated 5 
times and the standard deviation of the experiments was divided by the total cell number of 
the volume. To reflect modern stereology sampling techniques, we also simulated systematic 
uniform random sampling (SURS) stereology experiments. As compared to simple random 
sampling, SURS has a stricter subset of possible samplings. Rather than looking at any 
random subset of slices, SURS requires sampling the tissue with a fixed interval, while the 
first starting slice is randomly selected (Fig. 3A). In order to compare SURS with simple 
random sampling, each SURS experiment consisted of a specific number of digital slices. 
Since a specific number of digital slices can be attained by a variety of sample intervals, the 
minimum interval that would yield the desired number of slices was selected. Once the digital 
sections were selected for SURS, the cell density was calculated in the same manner as 
simple random sampling. To calculate the coefficient of variation, each SURS experiment 
was repeated for 5 random starting positions. Figure 3C shows only numbers of slices that 
yielded at least 5 possible starting positions. 
Quantifying the effect of amino alcohol (related to fig. S2): High levels of 
autofluorescence can overshadow elements of interest and lead to false inclusion of 
features. Intensity data from the mouse femur and tibia before and after treatment with 
amino alcohol (N,N,N',N'-tetrakis(2-hydroxypropyl) ethylenediamine) (Sigma, #122262-
1L) were analyzed. The starting depth (0 µm) was defined as the first section that contained 
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both sufficient compact bone and marrow for analysis. Then, for 7-9 depths along the 
imaging dimension, two areas (~ 1000 µm2) were extracted. The first area exclusively 
contained compact bone, while the other exclusively contained marrow. The mean 
intensities of the two areas (marrow and compact bone) were then calculated. The mean 
intensity ratio (marrow versus compact bone) was used to quantify the amino alcohol effect 
on quenching auto-fluorescence in the marrow, since amino alcohol operates on heme, 
which is found only in the marrow. To verify that amino alcohol did not quench 
endogenous fluorescence, we compared the same region of the bone before and after amino 
alcohol treatment (fig. S2). 
Quantifying imaging depth at different anatomical regions of the bone (related to fig. 
S6): Bone tissue is difficult to clear and image in 3D, particularly in deeper regions where 
the SNR is low. Additionally, bones are highly heterogeneous and different regions have 
significantly different biological makeup that affects imaging SNR. In order to characterize 
the imaging depth capabilities of LSFM in bone tissue cleared by Bone CLARITY, we 
quantitatively assessed cell detection in several anatomically distinct regions using a Peak 
SNR (PSNR) metric (equation 1).  
𝑃𝑆𝑁𝑅 = 20 × log10
𝑀𝐴𝑋−𝜇
𝜎
    (1) 
MAX is the maximum intensity of pixels in the region containing the cell, μ is the 
mean intensity of all pixels in the region that is at least 20 μm away from the cell center, and 
σ is their standard deviation. For each anatomical region, the starting point (0 µm) of the 
sample was defined as the first depth that bone tissue filled at least 50% of the field-of-view. 
Then, at least 10 isolated Sox9+ cells were selected along the image stack and their PSNR 
were calculated. For PSNR calculation, an area of 0.123 mm2 and 0.086 mm2 (for long bones 
and vertebrae, respectively) was used for the region around the cell. Based on visual 
inspection, the minimum PSNR for cell detection was 24. Consequently, we could reliably 
image bone tissue to a depth of approximately 1.5 mm. With the exception of chondrocyte-
dense regions such as the growth plate and the epiphysis, this demonstrates that Bone 
CLARITY and LSFM provide end-to-end imaging of mouse bone tissue. Note that in regions 
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with high concentration of chondrocytes, no isolated cells could be found, thus creating large 
gaps along the imaging depth in fig. S6E. 
Antibody staining: Mice were perfused transcardially with 0.01M PBS (Sigma, 
#P3813) followed by 4% paraformaldehyde (PFA) (VWR, #100496-496). The femurs and 
tibias were extracted and post-fixed overnight with 4% PFA. The bones were 
demineralized with 10% EDTA in 0.01M PBS (Lonza, #51234) for two weeks at 4 degrees 
with daily solution exchange. Afterwards, the bones were incubated in 30% sucrose 
(Sigma, #S0389) in 0.01M PBS until they equilibrated to the solution. Next, the bones were 
embedded in OCT compound (Sakura Finetek, #M71484) in a tissue mold cassette and 
slowly frozen in powdered dry ice containing ethanol (Sigma, #E7023). The bones were 
then cut along its longitudinal plane with a cryostat (Leica, Biosystems) until one-half 
remained. The OCT compound was removed from the bisected bone and cleared following 
the Bone CLARITY protocol starting with hydrogel embedding and ending before 
refractive index matching stage. Antibody staining was performed using an anti-
osteocalcin antibody (Abcam, #ab93876) at 1:100 in 0.5mM SDS with 0.01 % sodium 
azide (Ricca Chemical Company, #7144.8-16) for 2 days at room temperature. The bones 
were then washed for 2 days at room temperature using PBST (0.02% Triton-X100) and 
then incubated in secondary conjugated to Alexa-647 (Jackson Immuno Research, #711-
606-152) for 2 days. Samples were then washed for 2 days and incubated in RIMS stepwise 
from 1.38-1.47 over 3 days. Bones were then imaged using a Zeiss 780 confocal. 
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C h a p t e r  4  
Engineered adeno-associated viruses for efficient and noninvasive gene 
delivery throughout the central and peripheral nervous systems 
 
[1] Chan, K.Y.C et al. “Engineered adeno-associated viruses for efficient and noninvasive 
gene delivery throughout the central and peripheral nervous systems”. In press. 
 
4.1 Summary 
Recombinant adeno-associated viruses (AAVs) are commonly used for in vivo gene 
transfer. Nevertheless, AAVs that provide efficient transduction across specific organs or 
cell populations are needed. Here, we used the capsid selection method CREATE to identify 
AAV-PHP.eB and AAV-PHP.S, two capsids that efficiently transduce the central and 
peripheral nervous systems, respectively. In the adult mouse, intravenous administration of 
1 x 1011 vector genomes (vg) of AAV-PHP.eB transduced 69% of cortical and 55% of striatal 
neurons, while administration of 1 x 1012 vg AAV-PHP.S transduced 82% of dorsal root 
ganglion neurons, as well as cardiac and enteric neurons. The efficiency of these vectors 
facilitates stochastic, multicolor labeling of neurons, which can be used to assess individual 
cell morphology. To support such efforts, we provide methods for multicolor labeling of a 
tunable fraction of cells without compromising color diversity. Furthermore, we demonstrate 
that cell type-specific promoters can be used to expand the utility of these capsids across the 
nervous system. Collectively, these novel AAV tools enable efficient and versatile gene 
manipulation in the nervous system of transgenic and non-transgenic animals. 
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4.2 Introduction 
Adeno-associated viruses (AAVs)14 have been extensively used as vehicles for gene 
transfer to the nervous system enabling gene expression and knockdown, gene editing64,65, 
circuit modulation1,66, in vivo imaging67,68, disease model development69, and the evaluation 
of therapeutic candidates for the treatment of neurological diseases70. AAVs are well suited 
for these applications because they provide safe, long-term expression in the nervous 
system71,72. Most of these applications rely on local AAV injections into the adult brain to 
bypass the blood-brain barrier (BBB) and to temporally and spatially restrict transgene 
expression.  
Targeted AAV injections have also been used for gene delivery to peripheral neurons 
to test strategies for treating chronic pain73-75 and for tracing, monitoring, and modulating 
specific subpopulations of vagal neurons76,77. Many peripheral neuron populations, however, 
are difficult to access surgically (e.g., dorsal root ganglia (DRG), nodose ganglia, 
sympathetic chain ganglia, and cardiac ganglia) or are widely distributed (e.g., the enteric 
nervous system), thereby limiting methods for genetic manipulation of these targets. 
Likewise, in the CNS, single localized injections may be insufficient to study circuits in 
larger species78 or to test gene therapies for diseases that involve the entire nervous system 
or widely distributed cell populations (e.g., Parkinson’s, Huntington’s, amyotrophic lateral 
sclerosis, Alzheimer’s, spinal muscular atrophy, Friedreich’s ataxia, and numerous 
lysosomal storage diseases)70. 
 Systemic AAV delivery79,80 provides a non-invasive alternative for broad gene 
delivery to the nervous system; however, the high viral load required and relatively low 
transduction efficiency have limited wide adoption of this method. Several groups have 
developed AAVs that enhance gene transfer to the CNS after intravenous delivery. The 
recently reported AAV-AS capsid17, which utilizes a polyalanine N-terminal extension to the 
AAV9.4781 VP2 capsid protein, provides higher neuronal transduction, particularly in the 
striatum, which may have applications for Huntington’s disease. Similarly, the AAV-BR1 
capsid16, based on AAV2, may be useful for applications that require more efficient and 
selective transduction of brain endothelial cells. Using a cell type-specific capsid selection 
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method we developed called CREATE (Cre REcombinase-based AAV Targeted Evolution), 
we recently reported AAV-PHP.B, a capsid that transduces the majority of neurons and 
astrocytes across many regions of the adult mouse brain and spinal cord after intravenous 
injection18. While the efficiency of AAV-PHP.B opens up new possibilities for CNS-wide 
genetic modification, it requires a substantial dose of vector (e.g., 1 x 1012 vg per adult mouse 
or higher). 
Here, we used CREATE to further evolve AAV-PHP.B for more efficient 
transduction of neurons throughout the adult mouse brain and spinal cord. We describe a 
novel enhanced variant of AAV-PHP.B, AAV-PHP.eB, which lowers the viral load required 
to transduce the majority of CNS neurons. Notably, we also report the characterization of a 
second capsid variant, AAV-PHP.S, that displays improved tropism towards peripheral 
neurons, including those in the DRG, cardiac ganglia, and enteric nervous system.  
AAVs are also used for the bulk study of neuronal anatomical connectivity and morphology82 
and are components of multi-viral strategies for tracing the relationships between bulk inputs 
and outputs83,84. At the single-cell level, AAV-based multicolor labeling systems20 have been 
developed with the goal of improving tracing efforts. However, the lack of control over the 
labeling density and uniformity of color diversity has been a persistent challenge20. To 
overcome these challenges, we have developed a two-component viral vector system to 
stochastically label cells with a wide range of hues while independently controlling the 
fraction of cells labeled. In addition, using the novel capsids reported here, we expressed a 
variety of fluorescent reporters under different cell type-specific promoters, supporting the 
potential use of these vectors for population-wide genetic manipulations of the nervous 
system in Cre transgenic or wild-type mice.  
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4.3 Results 
Engineered AAV capsids for efficient transduction across the central and peripheral 
nervous systems  
 
 Here we report two novel AAV capsids that provide increased gene transfer to the  
CNS and the PNS via the vasculature. We developed these vectors by applying the previously 
published in vivo capsid selection method, CREATE18 (Fig. 1a) to AAV-PHP.B and AAV9 
as parental capsids. First, we sought to evolve the previously described AAV-PHP.B vector 
for more efficient tropism for the CNS. We generated an AAV capsid library in which the 
AAV-PHP.B 7-mer targeting sequence was modified by randomizing three consecutive 
amino acids (AAs) in an overlapping fashion across the 7-mer and flanking AAs (Methods). 
To provide selective pressure for capsids that transduce both neurons and glia, we subjected 
the library to parallel in vivo selections in adult Vglut2-IRES-Cre, Vgat-IRES-Cre, and 
GFAP-Cre mice, which express Cre in glutamatergic neurons, GABAergic neurons and 
astrocytes, respectively. After two rounds of selection, we found that a variant comprising 
the sequence DGT in place of the AAV-PHP.B sequence AQTLAVPFK at AA positions 587-
589 (Fig. 1b) was enriched in all three transgenic lines (11.1%, 12.1%, and 15.7% of the 
total recovered sequences, respectively). We used this DGT substitution variant or AAV-
PHP.B to package a single-stranded (ss) AAV reporter genome that expresses a nuclear-
localized GFP (NLS-GFP) from the constitutive CAG promoter, (ssAAV-CAG-NLS-GFP), 
and delivered 1 x 1011 vg of the viruses by intravenous injection to adult mice. We found that 
the DGT substitution variant appeared to transduce the CNS more efficiently than AAV-
PHP.B as judged by wide-field fluorescence microscopy of the intact brain (Fig. 1c) and 
confocal microscopy on thin sections from brain (Fig. 1f) and spinal cord (Fig. 1g). We refer 
to this enhanced AAV-PHP.B variant as AAV-PHP.eB and present further quantitative 
characterization below. Second, we performed a separate selection of an AAV9-based 7-mer 
library in GFAP-Cre mice18. After two rounds of selection, we found a variant (7-mer 
sequence – QAVRTSL, representing 33.3% of the total sequences recovered; Fig. 1b). As 
above, we evaluated the capsid against AAV9, its parent capsid, by packaging the ssAAV-
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CAG-NLS-GFP reporter and delivering the vectors at 1 x 1012 vg/mouse. While the 
QAVRTSL variant and AAV9 both showed similar sparse transduction of the brain (Fig. 1c, 
d), the QAVRTSL variant notably appeared to strongly transduce peripheral sensory 
afferents entering the spinal cord and brain stem (Fig. 1c-e). We refer to this variant as AAV-
PHP.S. While unexpected given the selection scheme, the improved tropism for sensory 
neurons provided by AAV-PHP.S could be useful for widespread gene transfer to cells of 
the PNS. We explore this possibility below.  
Together these data indicate that the tropism of AAV9 can be routed towards either 
more efficient CNS or PNS transduction (Fig. 1c), depending on the AA 
insertion/modification. A comparison of the AA insertion/modification sequences of AAV-
PHP.eB and AAV-PHP.S along with their parent capsids, AAV-PHP.B and AAV9, 
respectively, is shown in Fig. 1b, and their nucleotide sequences and relative viral production 
efficiencies are provided in (Supplementary Table 1). 
 
Quantification of transduction by AAV-PHP.eB and AAV-PHP.S 
Next, we quantified the transduction efficiency of AAV-PHP.eB and AAV-PHP.B 
three weeks after intravenous administration of 1 x 1011 vg of ssAAV-CAG-NLS-GFP. First, 
when compared with AAV-PHP.B, AAV-PHP.eB provided significantly increased (> 2.5-
fold) GFP fluorescence per cell nucleus throughout the cortex and striatum and (> 1.8-fold) 
in cerebellar Purkinje cells (Fig. 2d and Supplementary Fig. 1). To quantify expression in 
Purkinje cells, an automated cell segmentation and analysis pipeline was developed 
(Supplementary Fig. 2 and Methods). AAV-PHP.eB also showed an increase over AAV-
PHP.B in both the percentage of total cortical cells transduced (DAPI+ cells that express 
GFP; 51 ± 2% vs. 37 ± 3%; Fig. 2a,e) and the percentage of NeuN+ neurons transduced (69 
± 4% vs. 49 ± 7%; Fig. 2b,e). In the striatum, a similar trend towards increased transduction 
by AAV-PHP.eB compared to AAV-PHP.B was observed from quantifying both the 
percentage of DAPI+ and NeuN+ cells that express GFP (DAPI+: 42 ± 5% vs. 26 ± 5%; Fig. 
2a,e; NeuN+: 55 ± 7% vs 36 ± 8%, Fig. 2b,e). In the cerebellum, we observed an increase in 
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the percentage of Calbindin+ Purkinje cells that expressed GFP in mice injected with AAV-
PHP.eB as compared with AAV-PHP.B (76 ± 5% vs. 37 ± 10%, Fig. 2c,e). Both vectors 
transduced a similar percentage of S100+ glia in the cortex as well as the striatum (Fig. 2e 
and Supplementary Fig. 3).    
Next, we examined the transduction efficiency of AAV-PHP.S compared with 
AAV9, a vector known to provide broad transduction of the PNS and many peripheral organs 
after intravenous delivery79,85-87. We packaged ssAAV-CAG-NLS-GFP into AAV9 or AAV-
PHP.S, administered the viruses to adult mice by intravenous injection at 1 x 1012 vg/mouse, 
and then assessed GFP expression after three weeks. In the DRG, AAV-PHP.S provided a 
significant increase in transduction over AAV9 (Fig. 3a) as quantified both by native GFP 
fluorescence per cell nucleus (> 2.6-fold) (Fig. 3b) and by the percentage of cells positive 
for PGP9.5, a marker for neurons in the PNS, that co-expressed GFP (82 ± 2% vs. 46 ± 0.7%) 
(Fig. 3c). AAV-PHP.S also transduced the cardiac ganglia (Fig. 3a) and cells within the 
enteric nervous system of the small intestine and colon (Fig. 3d and Supplementary Movie 
1) with high efficiency. To determine the identity of enteric nervous system cells transduced 
by AAV-PHP.S, we performed immunohistochemistry (IHC) for the neuronal marker 
PGP9.5 and the astrocyte marker S100b. The majority of GFP+ cells within the myenteric 
plexus (Fig. 3d) and submucosal plexus (Supplementary Fig. 4) of the small intestine and 
colon co-localized to PGP9.5+ cells with sparse and faint transduction seen in S100b+ cells 
(Supplementary Movie 1). Notably, we also observed robust transduction by AAV-PHP.S 
of cells in many organs, including the liver, lungs, heart, and stomach cells within the muscle 
and myenteric plexus layers (Supplementary Fig. 4).  
AAV-PHP.eB and AAV-PHP.S enable efficient co-transduction of neurons  
The increased transduction efficiency and enhanced expression per cell observed 
with both AAV-PHP.eB and AAV-PHP.S, relative to their parental capsids, suggested that 
a large fraction of cells are transduced by multiple AAV genomes when administered at the 
above doses. If true, the transduction efficiency of these vectors may enable applications that 
require expression from more than one AAV genome. To test this, we co-administered a 
cocktail of three AAV genomes with the single fluorescent proteins (XFPs) mRuby2, 
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mNeonGreen, and mTurquoise2 expressed from the human Synapsin (hSyn1) promoter, 
which limits expression to neurons. The three-vector mix (AAV-hSyn1-3XFP) was 
packaged into AAV-PHP.eB or AAV-PHP.S and injected into adult wild-type mice. Co-
administration of these vectors resulted in dense labeling of cells with multiple colors in the 
brain when delivered with AAV-PHP.eB and in the enteric nervous system with AAV-
PHP.S (Fig. 4a). Because cells transduced by a single vector would express only one of the 
three XFPs, and thereby be red, green or blue, the wide color diversity seen in both the brain 
and the enteric nervous system demonstrates that these novel capsids enable the independent 
and stochastic co-transduction of neurons by multiple viral vectors. 
 
Tunable density multiplexed gene expression 
Multicolor labeling by AAVs can benefit single-cell morphology and tracing 
studies88. However, direct local virus injections20,82 may not provide uniform color diversity 
because of the non-uniform distribution of vector copies radiating outward from the injection 
site20. We predicted that systemically delivered AAVs may offer a solution to this challenge 
because the distribution of labeled cells and color diversity would be more uniform. Indeed, 
when we delivered three separate XFPs expressed from the CAG promoter (AAV-CAG-
3XFP; Fig. 4b) we observed a wide range of hues in the cortex, striatum, and cerebellum 
(Fig. 4d, left). However, this strategy, where the expression of the transgene is controlled in 
cis, couples the expression level, labeling density, and the color diversity to the virus dose. 
As expected, when we lowered the virus dose we observed that the density and color diversity 
were reduced (i.e., most cells were labeled by primary colors – red, green, or blue – likely 
reflecting single transduction events) (Fig. 4d, right). Therefore, to achieve stochastic, 
multicolor labeling while reducing the fraction of labeled cells, we sought a two-component 
AAV system in which the expression of XFPs in each cell is dependent on a separate inducer 
vector that is co-transduced at a variable dose. In this way, color diversity could be decoupled 
from the labeling density. We developed two inducer systems: one that uses the tetracycline 
(tet)-inducible system – a tet-off transactivator (tTA) and a tet-responsive element (TRE)89 
(Fig. 4c) – and a second that uses the FLPo-FRT system90 (Supplementary Fig. 5). 
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Importantly, both systems should allow for cell type-specific expression through the use of 
FLEX/DIO vectors and the extensive collection of Cre transgenic animals available (e.g., 
JAX, ABI, and GENSAT). 
The tTA-TRE based system relies on co-administration of three separate vectors with 
XFP expression driven by a TRE containing promoter, along with an adjustable dose of an 
AAV-tTA expression vector. To evaluate this approach, we co-administered ssAAV-TRE-
mNeonGreen along with a ssAAV-CAG-tTA vector. We delivered ssAAV-TRE-
mNeonGreen at the same dose across all animals while varying the dose of the ssAAV-CAG-
tTA inducer. We observed a dose-dependent reduction in the density of cells expressing 
mNeonGreen two weeks after intravenous delivery of the two vectors (Supplementary Fig. 
6). Similar results were achieved with the two-component FLPo-FRT system 
(Supplementary Fig. 5). Although both systems are viable, we focused on the tTA-TRE 
system because (1) the short (417 bp) TRE promoter is compatible with longer transgenes 
and (2) the added versatility of providing higher levels of expression with a positive-feedback 
loop in the AAV-tTA vector (Supplementary Fig. 7). However, care should be taken with 
long-term use of the tTA-TRE overexpression system to avoid the potential toxicity seen 
with overexpression of the tTA91.  
We next sought to test the tTA-TRE system with multi-color labeling. Using the same 
3XFP cocktail described above (Fig. 4a), we generated three AAV-TRE-XFP genomes and 
delivered the vectors at a high dose to all animals, along with either 1 x 1011 or 1 x 1010 
vg/animal of a neuron specific inducer vector (ssAAV-PHP.eB:hSyn1-tTA). Three weeks 
after intravenous administration we observed robust and inducer dose-dependent labeling 
(Fig. 4e). Even at the lower inducer dose, and in contrast with the single-component 
expression system (Fig. 4d), many cells expressed more than one of the three XFP 
transgenes. We quantified the fraction of cells that contained each XFP and found that, with 
the two-component system at a low inducer dose, at least 42% of the labeled cells within the 
cortex, striatum, and the Purkinje cell population expressed all three XFPs. In comparison, 
in the one-component system, less than 10% of the labeled cells in the cortex and 1% of cells 
in the striatum and the Purkinje cell population expressed all three XFPs (Fig. 4f).  Finally, 
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we utilized the two-component system to trace mitral cells in the olfactory bulb of an adult 
Tbx21-Cre mouse, a transgenic line that labels mitral and tufted cells in the olfactory bulb. 
Three weeks after intravenous administration of 1 x 1012 vg/animal of a cocktail of TRE-
DIO-XFPs and 1 x 1010 vg/animal of AAV-ihSyn1-tTA, a positive feedback inducible tTA 
driven by the hSyn promoter, we observed multicolor labeling at a density that facilitated 
segmentation of several local dendritic arbors after tissue clearing (Fig. 4g). 
 
A versatile AAV toolbox with cell-type specific promoters   
A further advantage of systemic AAV administration is that it provides a means to 
transduce populations of specific cell types even if the cells are distributed broadly. As a 
proof-of-concept that AAV-PHP.eB can be used to achieve cell type-restricted expression 
across the brain, we co-administered three ssAAV genomes that each expressed a spectrally 
distinct XFP controlled by a different cell type-specific promoter. In this way, we were able 
to independently express distinct transgenes in neurons (hSyn1), astrocytes (GFAP), and 
oligodendrocytes (MBP) within the same animal (Fig. 5a). We also packaged AAV vectors 
containing previously published promoters that restrict reporter expression to 
catecholaminergic cells (mouse tyrosine hydroxylase; mTH), serotonergic cells (FEV 
promoter; Ple67), Purkinje cells (PCP2 promoter; Ple155)92, or GABAergic interneurons 
within the forebrain (mouse distal-less homeobox; mDlx5/6)93  and administered these 
intravenously (Fig. 5b-f).  We provide quantification of the specificity and efficiency of 
reporter transduction using these gene regulatory elements in Figure 5f. 
Similarly, to achieve cell type-restricted expression within the PNS, we used AAV-
PHP.S to co-administer the 3XFP cocktail under the control of the hSyn1 promoter (ssAAV-
PHP.S:hSyn-3XFP) or by expressing the 3XFP cocktail from the CAG promoter in a double-
floxed inverted open reading frame (ssAAV-PHP.S:CAG-DIO-3XFP) for expression in 
cholinergic neurons when used with ChAT-IRES-Cre transgenic mice (Supplementary Fig. 
8). Using this strategy together with the two-component TRE-tTA system described above, 
we were able to sparsely label cholinergic neurons within the myenteric plexus in the 
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proximal colon and trace the processes of multiple neurons for several millimeters 
(Supplementary Fig. 8). 
In Supplementary Table 2, we summarize the available constructs presented here, 
along with their applications within this paper. 
 
4.4 Discussion 
Using the previously described CREATE18 selection method, we have developed and 
characterized two novel capsids, AAV-PHP.eB and AAV-PHP.S, that enable efficient and 
noninvasive gene delivery throughout the CNS or PNS and visceral organs, respectively 
(Fig.1 and Supplementary Fig. 4). As in our prior study18, these variants were identified 
after only two rounds of in vivo selection, further demonstrating how CREATE can be used 
to identify AAV capsids with enhanced transduction properties. 
Previously, we selected for AAV capsids that more efficiently crossed the BBB and 
transduced GFAP-expressing astrocytes. Several of the identified variants, most notably 
AAV-PHP.B, also transduced neurons, although in general not with the same efficiency. In 
the current work, we sought to improve neuronal transduction while maintaining strong 
astrocytic transduction by performing parallel selections for capsids that transduced two 
widely distributed glutamatergic and GABAergic neuronal populations as well as astrocytes. 
This led to the development of the AAV-PHP.eB capsid, a variant that was consistently 
enriched through selections in each of the three Cre lines. Remarkably, AAV-PHP.eB differs 
from AAV-PHP.B at only two AAs adjacent to the original 7-mer insertion, yet at the 
relatively low systemic dose of 1 x 1011 vg/mouse it transduces the majority of neurons in 
the cortex and striatum, as well as over 75% of cerebellar Purkinje cells. The success of this 
approach suggests that the continued evolution of the AAV-PHP.B-based capsid using 
CREATE in multiple Cre lines is a viable strategy to improve transduction of other cell types, 
such as oligodendrocytes, while maintaining the overall CNS tropism.  
We also describe the AAV-PHP.S capsid, which we identified by selecting for 
capsids that transduce GFAP-expressing cells. Although the mechanism underlying the 
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selection of this variant is not clear, its discovery is nevertheless important; to date, there 
have been no reports of recombinant vectors capable of efficient, widespread transduction of 
peripheral neurons via systemic delivery in adult animals. Consequently, studies of PNS 
circuitry are arguably lagging behind those in the CNS. Many peripheral neuronal 
populations are challenging to access surgically, especially in small rodents, owing to their 
location94 or broad distribution95. For example, the DRG are a key target for gene therapy or 
genetic manipulation in the study of pain74,75. Our finding that AAV-PHP.S transduces at 
least 80% of DRG neurons should enable high coverage delivery of transgenes to multiple 
DRG. More broadly, AAV-PHP.S also transduces neurons in the enteric nervous system and 
in other peripheral ganglia, such as the cardiac ganglia, and could provide system-wide gene 
delivery to these populations, or to subsets of these populations when used with Cre 
transgenic lines or cell type-specific promoters. Encouragingly, several recent studies have 
demonstrated that the tools developed for studying the brain can also be applied to probe the 
function and projections of specific cell types within the PNS73,76,77. The importance of 
anatomically and functionally mapping the PNS has been recognized by the recent NIH 
initiative for Stimulating Peripheral Activity to Relieve Conditions (SPARC), and the novel 
tropism of AAV-PHP.S may bring about new strategies to modulate PNS circuits through 
genetic tools such as optogenetics1 or chemogenetics66. For example, systemic Flp- and Cre-
dependent effectors delivered via AAV-PHP.S to Cre transgenic animals or used in 
combination with circuit-specific retrograde Cre viruses should allow for circuit-based 
interrogation of PNS function and enable the types of experiments now routinely conducted 
in the CNS1,96.    
The improved transduction efficiency we observed from both AAV-PHP.eB and 
AAV-PHP.S relative to their parental capsids could be seen from both the increased number 
of transduced cells and the increased expression level per cell (Fig 2, 3 and Supplementary 
Fig. 1). The higher expression in individual cells likely results from an increased mean 
number of vector genomes per cell, as supported by the high frequency of cells that were 
labeled with multiple XFPs (Fig. 4a). This suggests that for applications that do not require 
high expression levels per cell, the viral doses could be lowered from those used in this study. 
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Lowering the viral load used for systemic gene delivery will reduce cost and production 
burden14 and minimize the risk for adverse reactions to the viral components97,98.  
As AAV vector engineering efforts continue to improve the efficiency of 
transduction of specific organs or cell populations99, widespread gene transfer will become 
a more viable alternative to the development of germline transgenics. To facilitate studies in 
nontransgenic animals, it will be necessary to develop additional vehicles with improved 
transduction efficiency and specificity and to identify gene regulatory elements that can be 
used to restrict expression to defined populations. Finding short enhancers that provide the 
expected restriction in expression has proven challenging100, but more recent efforts92 are 
expanding the collection of enhancer-promoters available. Here, we evaluated several gene 
regulatory elements and found that it was possible to achieve expression that was largely 
restricted to the expected cell types. If the separate vector components are translatable across 
species, vector-based genetic manipulations of specific cell types may become more feasible 
in genetically intractable organisms. Notably, in a recent study, intravenously administered 
AAV-PHP.B provided improved transduction of the rat CNS, relative to AAV9101. In a 
recent study, a Dlx5/6 enhancer was found to drive expression that was largely restricted to 
GABAergic neurons in the telencephalon of a panel of vertebrate species93. In this study, we 
further validate the Dlx5/6 enhancer vector for forebrain-wide GABAergic neuron 
expression when delivered using intravenous AAV-PHP.eB (Fig. 5e). 
Cell morphology both informs and determines cell function102,103, and numerous tools 
have been developed for morphology and connectivity applications104,105, especially in the 
brain106,107. To enable tracing of cellular processes, sparse labeling of cells has been a key 
enabler – whether this comes from restricted gene or dye delivery (e.g. single-cell 
electroporation108,109) or from stochastic multicolor labeling and color-channel 
separation20,106,107. Both viral and transgenic approaches have been employed to address this 
problem. Although transgenic mice with sparse gene expression110,111 are useful, AAVs20 
provide a versatile platform that can be quickly customized with up-to-date tools, promoters, 
and recombinase-dependent expression control systems. Furthermore, vectors can be 
delivered through different routes or at a specific dose to control the location and fraction of 
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cells labeled. For these reasons, we developed an AAV-based expression system that allows 
for sparse multicolor labeling. This system uses two AAV components: a cocktail of XFP 
encoding vectors that exist in the off-state until induced by a second AAV vector that can be 
delivered at an empirically determined dose to provide expression in the desired fraction of 
co-transduced cells. We demonstrated that this system is well suited to the use of systemically 
delivered AAV-PHP.eB and AAV-PHP.S to achieve relatively uniform and sparse 
expression in the CNS and PNS. In addition, decoupling the relationship between the labeling 
density and the expression level may have additional applications. For example, sparse, high-
level expression could be beneficial for in vivo monitoring of neural activity with genetically 
encoded activity indicators by lowering the background fluorescence during wide-field 
imaging112 or large area 2-photon imaging113. Furthermore, a similar framework could be 
applied to the understanding of how neuronal circuitry and morphology change during 
normal and diseased states. Future applications of this two-component approach could also 
be used to achieve intersectional gene expression in defined populations through circuit-
specific delivery of one or both components or through the use of unique capsid-promoter or 
capsid-capsid combinations that serve to restrict expression to more specific populations.  
Overall, the vector resources we present here expand the AAV toolbox for the genetic 
modification of neurons with the central and peripheral nervous systems. 
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4.5 Main Figures 
 
Figure 1. Engineered AAV capsids for efficient transduction across the peripheral and 
central nervous systems. (a) Schematic of the CREATE selection method. (b) The amino 
acid (AA) sequences for the 7-mer insertions and flanking sequences for AAV-PHP.S, .B 
and .eB; the 7-mer and adjacent substitutions are highlighted in colored text. (c-g) ssAAV-
CAG-NLS-GFP was packaged into the indicated capsid and intravenously injected into adult 
mice at 1 x 1012 vg/mouse (AAV9 and AAV-PHP.S; c-e) or 1 x 1011 vg/mouse (AAV-PHP.B 
and AAV-PHP.eB; c, f, and g). (c) Representative whole brains imaged by wide-field 
fluorescence microscopy, with similar imaging and display parameters across all four brains. 
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Imaging was performed after three weeks of expression. (d-g) Representative confocal 
images of native GFP fluorescence from sagittal brain sections (d and f) and transverse spinal 
cord sections (e and g) are shown for the indicated capsids. For (d-g), all imaging and display 
conditions are matched across panel pairs to allow for comparisons. Panels (d) and (f) are 40 
µm maximum intensity projections (MIPs) and panels (e) and (g) are 300 µm MIPs. Scale 
bars for (c-e) are 1 mm.  
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Figure 2. AAV-PHP.eB transduces several CNS regions more efficiently than AAV-
PHP.B. ssAAV-PHP.B:CAG-NLS-GFP or ssAAV-PHP.eB:CAG-NLS-GFP was 
intravenously injected into adult mice at 1 x 1011 vg/mouse. Native GFP fluorescence was 
assessed after three weeks of expression. (a and b) Representative images of native GFP 
fluorescence (green) and DAPI staining (a, magenta) or NeuN staining (b, magenta) in the 
cortex and striatum. (c) Representative images of Calbindin immunohistochemistry (IHC) 
(magenta) in the cerebellum. (d) The mean of the median GFP intensity in all DAPI+ cells in 
the cortex and striatum or in Calbindin+ cells in the cerebellum. (e) Quantification of cell 
transduction. From left to right: The percentage of DAPI+ cells that express GFP in the 
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cortex: 51 ± 2% and 37 ± 3% for AAV-PHP.eB and AAV-PHP.B, respectively (p = 0.0034) 
and striatum:  42 ± 5% and 26 ± 5% for AAV-PHP.eB and AAV-PHP. B, respectively (p = 
0.0541). The percentage of NeuN+ cells that express GFP in the cortex: 69 ± 4% and 49 ± 
7% for AAV-PHP.eB and AAV-PHP.B, respectively (p = 0.037) and in the striatum: 55 ± 
7% and 36 ± 8% for AAV-PHP.eB and AAV-PHP.B, respectively (n.s., p = 0.128). The 
percentage of Calbindin+ cerebellar Purkinje cells that express GFP: 76 ± 5% and 37 ± 10% 
for AAV-PHP.eB and AAV-PHP. B, respectively (p = 0.039). The percentage of S100+ cells 
that express GFP in the cortex and striatum (p = 0.6738 and 0.1814). (d and e) For 
quantification: n = 4 mice per group, mean ± SEM, unpaired, parametric t-test (***p ≤ 0.001; 
**p ≤ 0.01; *p ≤ 0.05; n.s., p ≥ 0.05). All images were single-plane confocal images of native 
GFP fluorescence. Scale bars are 50 µm (a and b) and 100 µm (c). 
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Figure 3. AAV-PHP.S efficiently transduces peripheral neurons. ssAAV-PHP.S:CAG-
NLS-GFP or ssAAV9:CAG-NLS-GFP was intravenously injected into adult mice at 1 x 1012 
vg/mouse. Native GFP fluorescence was assessed after three weeks of expression. (a) 
Representative images of GFP expression and neuronal PGP9.5 (left, magenta) or DAPI 
(right, magenta) staining in a dorsal root ganglion (DRG, left) and cardiac ganglion (right). 
(b) Quantification of the mean of the median GFP fluorescence intensity per cell with AAV-
PHP.S or AAV9. (c) Quantification of the percentage of PGP9.5+ cells transduced by AAV-
PHP.S and AAV9; mean ± SEM. (d) Representative images of GFP expression, with 
neuronal PGP9.5 (red) and astrocyte S100b (blue) staining in the myenteric plexus of the 
duodenum, jejunum, lleum and proximal colon. In (b and c) means were compared with 
unpaired parametric t-tests; n = 3 independent animals per group. All imaging and display 
conditions are matched in the GFP channel across panel pairs. Scale bars in (a and d) are 50 
µm. 
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Figure 4. AAV-PHP.eB and AAV-PHP.S transfer multiple genomes per cell and enable 
tunable multicolor labeling with a two-component system. (a) Co-administration of a 
cocktail of three ssAAV vectors that each express one of three XFPs (top, schematic) from 
the hSyn1 promoter labels individual cells with a range of hues. Representative images are 
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shown of the cortex (left, AAV-PHP.eB; total dose: 4 x 1011 vg) and the enteric nervous 
system (right, AAV-PHP.S; total dose: 1 x 1012 vg). The inset box in gray is a high 
magnification view that highlights the dense network of discernable individual neurites 
labeled with a range of hues (b) Schematic of a one-component system where expression of 
the transgene is dependent on a cis regulatory element. (c) Schematic of the two-component 
system based on the tTA-TRE inducible system. Expression from the TRE-XFP vectors is 
dependent on co-transduction with a tTA (tet-off) inducer vector that contains a positive 
feedback loop to increase tTA expression (ssAAV-PHP.eB:ihSyn-tTA). The tTA protein 
(magenta hexagons) binds to TRE elements (blue lines) present on both the inducer and XFP 
vector. The dosage of the inducer vector can be varied, allowing sparse or dense gene 
expression. (d) Representative images of the cortex, striatum, and cerebellum using the one-
component expression system with a 3XFP cocktail expressed from the CAG promoter at an 
equal dose per XFP (high: total dose = 2 x 1011 vg; low: total dose = 1 x 1010 vg). (e) 
Representative images of the cortex, striatum, and cerebellum using the two-component 
system. The co-administered cocktail of viruses included 1 x 1012 total of the TRE-3XFP 
cocktail and a high (1 x 1011 vg) or low (1 x 1010 vg) dose of the tTA inducer. (f) Percentages 
of individual cells in each condition that express one (gray), two (yellow), or all three (white) 
XFPs. (g) MIP (left) of a coronal section from the olfactory bulb of a Tbx21-Cre mouse 
transduced with a cocktail of ssAAV-PHP.eB:TRE-DIO-3XFP (1 x 1012 vg total dose) and 
sAAV-PHP.eB:ihSyn-tTA (1 x 1010 vg). The morphologies of local neuronal dendritic arbors 
were traced with NeuTube and imported into Imaris v8.3 for 3D rendering (middle). An 
overlay is provided (right). Traced neurons are color-matched across panels in (g). Scale bars 
(d and e) are 50 µm and are MIPs of 40 µm z-stacks. The total volume in (g) is 0.042mm3. 
All images were acquired on tissue extracted three weeks after intravenous delivery in adult 
mice, except for (a) where the expression was assessed after 11 days.  
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Figure 5. AAV-PHP.eB can be used with gene regulatory elements to achieve cell type-
restricted gene expression throughout the brain. (a) Images show example cell type-
specific promoters driving XFPs delivered as ssAAV-PHP.eB:Promoter-XFPs within the 
same animal (intravenous injection of 1 x 1012 vg per viral vector). Image is from the striatum 
of an adult C57Bl/6 mouse after 3 weeks of expression. (b) Ple67, a FEV/serotonin cell type-
specific promoter driving GFP (ssAAV-PHP.eB:Ple67-GFP) was intravenously delivered at 
1 x 1012 vg and colocalized to serotonergic neurons by  IHC for serotonin (5-
hydroxytryptamine, 5-HT, magenta). A whole midbrain coronal slice (left) is shown with the 
dorsal raphe nucleus (DRN) outlined in blue and expanded for detail (right). (c) A mouse 
tyrosine hydroxylase (TH) promoter (mTH) driving GFP (ssAAV-PHP.B:mTH-GFP) was 
intravenously injected at 1 x 1012 vg and imaging was performed after 2 weeks of expression. 
Native GFP fluorescence (green) is shown together with IHC for TH (magenta). Images 
show the substantia nigra pars compacta (SNc, left) and ventral tegmental area (VTA, right) 
in the midbrain. (d) A vector with a Purkinje cell-selective promoter (Ple155, Pcp2) driving 
GFP (ssAAV-PHP.eB:Ple155-GFP) was intravenously injected at 1 x 1012 vg and expression 
was examined at 4 weeks. Native GFP fluorescence (green) can be seen in Purkinje cells 
throughout the cerebellum within a whole sagittal section (left) and at higher resolution of 
the red boxed region (right). (e) A vector with a GABAergic interneuron specific enhancer 
within the forebrain driving nuclear-localized mRuby2 (mDlx-NLS-mRuby2) was 
intravenously injected at 3 x 1011 vg and expression was examined at 8 weeks. Native NLS-
mRuby2 expression is seen within the forebrain (red, left) and colocalized to interneurons 
that are GAD67+ in the cortex (green, right). The scale bars in (a; b, right; c; d, right; e, right) 
are 50 µm. For (b and d, left) the scale bars are 1 mm. All panels are confocal images of 
native XFP fluorescence. (f) Summary table for FEV/Ple67, mTH, mDlx detailing the 
dosage, promoter length, transduction efficiency and specificity in the DRN, median raphe 
nucleus (MRN), VTA, SNc, cortex (CTX), and hippocampus (HIP).  
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4.6 Supplementary figures 
 
Supplementary Figure 1. AAV-PHP.eB transduces several brain regions more 
efficiently than AAV-PHP.B. (a-c) The cumulative distribution plots show native GFP 
a
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fluorescence, measured by the median NLS-GFP intensity within individual nuclei in the 
cortex (a), striatum (b) and within Calbindin+ Purkinje cell bodies (c). In (a and b), ROIs 
were drawn manually around each DAPI+ nuclei. In (c), the ROI detection was automated 
(see Methods and Supplementary Fig. 2). (a-c) The dotted lines represent the 50% 
intersect, where 50% of the cells have the corresponding median intensity or lower. (c) The 
solid black vertical line displays the cutoff point used during the automated detection to 
classify whether a cell had been transduced with ssAAV-CAG-NLS-GFP. Cells with a 
median intensity below or equal to 0.1 were classified as non-transduced while those above 
0.1 were classified as transduced. (a-c) N = 4 individual animals per group. P ≤ 0.0001 for 
each region, Kolmogorov-Smirnov test. 
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Supplementary Figure 2. An automated cell detection pipeline used for counting 
Purkinje cells in the cerebellum. The pipeline used for automated cell body and nucleus 
detection. (a) To detect cell bodies from the original image, a morphological filter with a 
disk-shaped structural element is first used to blur thin fibrous processes (morphological 
filtering). A circular Hough transform was subsequently applied to the filtered image 
(circular object detection). Red circles indicate the objects detected each of which 
corresponds to a single cell body. (b) In Fig. 2c, we further analyzed the GFP channel to 
detect the nucleus of each cell. First, the same area at each cell body region was cropped 
from the GFP image (cropped image of each cell body). The background of each cropped 
image, estimated by 2D Gaussian smoothing with a standard deviation of 5-fold the cell body 
size, was subtracted (background subtraction). After thresholding the image to make it binary 
(binarization), the 2-D convex hull of the object (convex hull) was obtained as the final 
nuclear region (NLS).  
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Supplementary Figure 3. Representative immunohistochemistry in the cortex and 
striatum after transduction with AAV-PHP.B or AAV-PHP.eB. Single-plane confocal 
images of native GFP fluorescence (green) after immunohistochemistry (IHC) with DAPI 
(DNA labeling, blue), NeuN (neuronal marker, magenta) and S100 (glial marker, red) in (a) 
cortex or (b) striatum. These data are presented in support of Fig. 2. All scale bars are 50 
µm. All imaging and display conditions for the GFP channel are matched across panel pairs 
to allow for comparisons. All images are from tissue extracted at three weeks post 
intravenous administration of ssAAV-CAG-NLS-GFP at 1 x 1011 vg to adult mice.  
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Supplementary Figure 4. AAV-PHP.S transduces peripheral organs through 
intravenous delivery in adult mice. (a) Representative images of the liver, lungs and 
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cardiac muscle transduced by AAV9 (top) or AAV-PHP.S (bottom). (b) Representative 
images of several layers of the stomach (longitudinal muscle, myenteric plexus, and circular 
muscle) transduced by AAV9 (top) or AAV-PHP.S (bottom). The myenteric plexus also 
contains muscle cells due to the uneven topography of the stomach. (c) Representative 
images of the submusocal plexus stained with neuronal marker PGP9.5 (red) and astrocyte 
marker S100b (blue) in the duodenum, jejunum, ileum, and proximal colon. (a-c) All images 
show native GFP fluorescence taken with confocal microscopy. Images in (a) are 20 µm 
maximum intensity projections (MIPs) and images in (b and c) are single-plane images. All 
imaging and display conditions for the GFP channel are matched across panel pairs to allow 
for comparisons. All scale bars are 50 µm. All images are from tissue extracted three weeks 
post intravenous administration of ssAAV-CAG-NLS-GFP at 1 x 1012 vg to adult mice. All 
experiments and imaging for direct comparisons were performed in parallel.  
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Supplementary Figure 5. The FLPo-FRT two-component system allows for sparse gene 
expression. (a) Schematic of the two viral vectors used for sparse gene expression with FlpO 
recombinase encoded in one viral vector and a transgene flanked by FRT sites on a second 
viral vector. In the basal state, the XFP is expressed in a double inverted orientation (fDIO) 
and upon the presence of FLPo is inverted into the orientation in line with the CAG promoter 
for expression. (b) Representative images of native mNeonGreen fluorescence two weeks 
after intravenous administration of ssAAV-PHP.B:CAG-fDIO-mNeonGreen at 1 x 1012 
vg/mouse together with the indicated dose of ssAAV-PHP.B:EF1α-FLPo. (c) Magnified 
images of the cortex, striatum, and cerebellum. Scale bars are 1 mm (b) and 50 µm (c).  
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Supplementary Figure 6. The use of the tetracycline-inducible system with viral vectors 
provides tunable dense-to-sparse gene expression. (a) A two-component vector system 
consisting of one virus, ssAAV-PHP.B:TRE-mNeonGreen, delivered at 1 x 1012 vg into 
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The use of the tetracycline-inducible system with viral vectors 
provides tunable dense-to-sparse gene expression
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adult mice, and a second virus, ssAAV-PHP.B:CAG-tTA, the dose of which was varied 
across mice. As a control, ssAAV-PHP.B:TRE-mNeonGreen was delivered alone to observe 
any basal expression from the ssAAV-PHP.B:TRE-mNeonGreen. All experimental, imaging 
and display conditions are matched across images. (b) Representative 20 µm MIPs of native 
mNeonGreen fluorescence from the cortex, striatum, and cerebellum at high and low 
activation doses. (c and d) Measurements of the shortest cell-to-cell distance (c) and cell 
density (d) in the cortex, striatum and cerebellum. N = 3 sections per group, mean ± 
SEM,unpaired t-test (***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05; n.s., p ≥ 0.05). (e) A MIP image 
of a coronal section taken from the olfactory bulb of a Tbx21-Cre mouse transduced with a 
cocktail of ssAAV-PHP.eB:TRE-DIO-3XFP (1 x 1012 vg total dose) and sAAV-
PHP.eB:ihSyn1-tTA (1 x 1010 vg – high dose) or (1 x 108 vg – low dose). In (e, right) the 
inset box in gray represents a high magnification of the region of interest outlined. Scale bars 
are 1 mm (a) and 50 µm (b and e). All images are native GFP fluorescence taken with 
confocal microscopy.  
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Supplementary Figure 7. A positive feedback loop within the tTA inducer vector 
enhances gene expression. Schematic of the two-component viral vector system without (a) 
and with (b) an inducible positive feedback loop with the viral vector containing the tTA. 
The schematic shows tTA protein (magenta hexagons) binding onto TRE elements (blue 
lines) to activate expression of (a) mNeonGreen or (b) mNeonGreen and the tTA containing 
vector. (c) Representative confocal images of sagittal brain sections transduced by the no-
feedback vector and (d) positive-feedback tTA vector at 1 x 109 vg. Both tTA inducers were 
co-administered with 1 x 1012 vg of the mNeonGreen viral vector. Scale bar in (c) is 1 mm.  
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Supplementary Figure 8. Cell type-restricted expression and sparse labeling in the 
enteric nervous system using AAV-PHP.S together with neuron-specific gene 
regulatory elements or Cre transgenic mice. Images show XFP expression within the 
myenteric plexus. (a) ssAAV-PHP.S:hSyn1-3XFP was administered intravenously at a total 
dose of 1 x 1012 vg. (b) ssAAV-PHP.S:CAG-DIO-3XFP was administered intravenously at 
a total dose of 1 x 1012 vg to ChAT-IRES-Cre transgenic mice to achieve cell type-specific 
expression in cholinergic neurons. (c) Sparse labeling in the proximal colon of a ChAT-IRE-
Cre transgenic using ssAAV-PHP.S-TET-DIO-3XFP at 1 x 1012 vg and ssAAV-PHP.S-
ihSyn-DIO-tTA at 1 x 1010 vg. Color-coded square boxes display neurons traced manually 
in Imaris v8.3. (d) Rectangular boxes show higher magnification views of regions highlight 
how sparse multicolor labeling facilitates tracing of closely aligned processes. Double arrows 
mark traced processes. Scale bars in (a and d) are set to 50 µm and in (c) to 200 µm. 
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4.7 Supplementary tables 
 
Supplementary Table 1. Capsid sequences, viral production efficiency, and Cre-
selection lines. The Cre-selection lines, amino acids, nucleotide sequences and average post-
production yields for AAV9, AAV-PHP.S, AAV-PHP.B and AAV-PHP.eB.  
  
SUPPLEMENTARY TABLE 1
Capsid sequences, viral production efficiency, and Cre-selection lines
Chan et al., 2017
Cre selection line(s) Amino acids*  Nucleotide sequence* 
% of total 
recovered sequences
Average post purification yield 
per 150mm dish (vg)
AAV9 Parent SAQ[7-mer]A AGTGCCCAA__(7-mer insertion)__GCA 1.28 x 10
12 
± 5.97 x 10
11
AAV-PHP.S GFAP-Cre SAQQAVRTSLA AGTGCCCAACAGGCGGTTAGGACGTCTTTGGCA 33% 4.11 x 10
12 
± 1.31 x 10
12
AAV-PHP.B GFAP-Cre SAQTLAVPFKA AGTGCCCAAACTTTGGCGGTGCCTTTTAAGGCA 2.45 x 10
12 
± 1.02 x 10
12
AAV-PHP.eB
GFAP-,Vgat- and
Vglut2-Cre
SDGTLAVPFKA AGTGATGGGACTTTGGCGGTGCCTTTTAAGGCA
15.7%, 12.1%, and 
11.1%, respectively
3.06 x 10
12 
± 1.18 x 10
12
*Starting amino acid or codon for AAV9 = 586
Supplementary Table 1 – Cre-selection lines, capsid sequences, and viral production efficiency
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Supplementary Table 2. Summary of AAV resources. A summary of the AAV plasmids 
used within the paper and their corresponding usages, with figure references.  
  
Chan et al., 2017
SUPPLEMENTARY TABLE 2
Summary of AAV resources
Applications within paper Vector name pAAV- Expression class
TRE
a
-mTurq2
TRE-mNeonG
TRE-mRuby2
TRE-DIO-mTurq2
TRE-DIO-mNeonG
TRE-DIO-tdTomato
TRE-DIO-mRuby2
CAG-fDIO-mNeonG Flp dependent
CAG
b
-tTA
hSyn1
c
-tTA
ihSyn1
d
-tTA
ihSyn1-DIO-tTA
CAG-mTurq2
CAG-mNeonG
CAG-mRuby2
CAG-NLS-GFP-NLS
CAG-DIO-mTurq2
CAG-DIO-mNeonG
CAG-DIO-mRuby2
hSyn1-mTurq2
hSyn1-mNeonG
hSyn1-mRuby2
MBP
e
-eYFPf
MsTH
f
-GFP
GFAP
g
-mKate2.5f
mDlx
h
-NLS-mRuby2
a
TREpi = second generation tetracycline-regulated promoter 
b
CAG = synthetic promoter containing the cytomegalovirus early enhancer element, the promoter, f irst exon and first intron of chicken beta-actin 
gene, and the splice acceptor from the rabbit beta-globin gene 
c
hSyn1 = human Synapsin I promoter
d
ihSyn1 = inducible intron human Synapsin I promoter
e
MBP = myelin basic protein promoter
f
MsTH = mouse tyrosine hydroxylase promoter
g
GFAP = glial f ibrillary acidic protein promoter
h
mDlx = mouse distal-less homeobox promoter
• Expression of XFPs  that are constitutive or 
Cre-dependent  (Fig. 1c-g), (Fig. 2a-c), (Fig. 
3a,c), (Fig. 4d), and (Supplementary Fig. 4a-
c).
• Expression of XFPs under the control of cell 
type-specific gene regulatory elements (Fig. 
4a) and (Fig. 5a-e).
• Expression of XFPs that are tunable in the 
density of expression in a constitutive, cell 
type-specific, or recombinase dependent 
manner (Fig. 4e,g), (Supplementary Fig. 5a-
c), (Supplementary Fig. 6a,b),  
(Supplementary Fig. 7a-d), (Supplementary 
Fig. 8a-d). 
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4.8 Supplementary movie caption 
Supplementary Movie 1. AAV-PHP.S transduction across multiple layers of the small 
intestine. A video demonstrating the transduction of AAV-PHP.S across multiple layers of 
the small intestine after optical clearing with refractive index matching solution (RIMS). 
Native GFP fluorescence (green) from ssAAV-PHP.S:CAG-NLS-GFP at 1 x 1012vg/mouse 
is shown. S100b staining (magenta) is shown for contrast. (doi: 10.22002/D1.237)1 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 = data file stored at www.data.caltech.edu 
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4.9 Methods 
Animals  
 
All procedures were approved by the California Institute of Technology Institutional Animal 
Care and Use Committee (IACUC). Mice were purchased from Jackson Laboratory (JAX) - 
C57Bl/6J mice (000664), GFAP-Cre (012886)114, Vgat-IRES-Cre (016962)115, Vglut2-
IRES-Cre (016963)115, and Tbx21-Cre (024507)116. Male or female mice were used. Mice 
were randomly assigned to groups of predetermined sample size. All experiments with direct 
comparisons were performed in parallel to minimize variability. 
 
In vivo selection 
 
The AAV-PHP.eB capsid was identified by selecting for AAV-PHP.B variants that 
transduced cells in Vglut2-IRES-Cre, Vgat-IRES-Cre, and GFAP-Cre mice through two 
rounds of selection as previously described18. Intravenous administration of AAV vectors 
was performed by injection into the retro-orbital sinus of adult mice (6-8 weeks of age). The 
AAV-PHP.B capsid was modified by partial randomization of the original AAV-PHP.B 7-
mer insertion and 4 flanking AAs (AAV-PHP.B AA positions 587 - 597). The AAV-PHP.B-
based library was generated by PCR using primer XF18 and a mixture of 5 primers identical 
to the AAV-PHP.B template sequence with the exception of mixed bases at 3 consecutive 
randomized codons (NNK). In each primer mix, the position of the 3 randomized NNK 
codons was shifted by 6 bp (2 codons) such that each position in the 7-mer and the 2 AAs on 
each side of the 7-mer AAs were randomized, 3 AA at a time, in an overlapping manner. An 
equal amount of each of the 5 PCR products was assembled into the AAV-(delta)Cap-in-cis 
lox acceptor vector using the NEB Hi-Fi DNA Assembly Master Mix (New England Biolabs 
E2621) and used to generate the AAV-PHP.B-based AAV library. AAV-PHP.S was 
generated from an insertion of a random 7-mer between the 588-589 site of AAV9 and was 
identified from two rounds of in vivo selection in GFAP-Cre mice18.   
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Plasmids 
 
The backbones of all AAV plasmids that are double inverted orientation (DIO) were based 
on pAAV-Ef1a-DIO EYFP (Addgene, #27056), and all non-DIO plasmids were based on 
pAAV-EF1a-Cre (Addgene, #55636). The backbone of pAAV-CAG-fDIO-mNeonGreen 
was based on pAAV-Ef1a-fDIO EYFP (Addgene, #55641). The fluorescent protein cDNAs 
for mTurquoise2117, mNeonGreen118, mRuby2119, or mKate2.5 were synthesized as gBlocks 
(Integrated DNA Technologies). The MBP-eYFPf and GFAP-mkate2.5f vectors have a 
farnesylation sequence attached by overhang PCR. The pAAV-CAG-NLS-GFP vector was 
modified by PCR to add N- and C-terminal NLS sequences and assembled using NEB Hi-Fi 
DNA Assembly Master Mix (New England Biolabs E2621). The mouse tyrosine 
hydroxylase (TH) promoter (mTH) was based on the 2.5 kb region of a published rat TH 
promoter120 and myelin basic promoter (MBP)121. Both were directly cloned from mouse 
genomic DNA. The hSyn1 promoter122 was cloned from pAAV-hSyn Con/Foff EYFP 
(Addgene, #55651). The GFAP (GfABC1D) promoter was previously described
123 and was 
cloned upstream of a synthetic intron. The GFAP-mKate2.5 plasmid also contained 3 tandem 
copies of sequences complementary to 6 miRNAs: miR-1, miR-122, miR-375, miR-196a, 
miR-743 and miR-10b inserted between the WPRE and an SV40 pA sequence. The TRE 
was PCR amplified from a SG-TRE containing plasmid89. The inducible hSyn1 (ihSyn1) 
promoter was cloned by overlap PCR with the hSyn1 promoter, and oligonucleotides 
designed with a synthetic intron and 3 tetO binding sites. The AAV vectors expressing GFP 
from the Ple67 and Ple155 promoters were obtained from (Addgene, #49138 and #49140, 
respectively).  The AAV-mDlx-NLS-mRuby vector was cloned by replacing the GFP 
reporter in pAAV-mDlx-GFP-Fishell-1 (Addgene, #83900) with a mRuby reporter fused 
with an N-terminal SV40 NLS. 
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Virus production and purification 
 
AAVs were generated in HEK 293T cells (ATCC) using Polyethylenimine (PEI)124. 72 hours 
post transfection, viral particles were harvested from the media and after 120 hours from 
cells and the media. Viral particles from the media were precipitated with 40% polyethylene 
glycol (Sigma, 89510-1KG-F) in 500 mM NaCl and combined with cell pellets for 
processing. The cell pellets were suspended in 500 mM NaCl, 40 mM Tris, 2.5 mM MgCl2, 
pH 8, and 100 U/mL of salt-activate nuclease (Arcticzymes) at 37°C for 30 minutes. 
Afterwards, the cells were clarified by centrifugation at 2,000 x g and then purified over 
iodixanol (Optiprep, Sigma; D1556) step gradients (15%, 25%, 40%, and 60%)125. Viruses 
were concentrated using Amicon filters (EMD, UFC910024), and formulated in sterile 
phosphate buffer saline (PBS). Virus titers were measured by determining the number of 
DNAse I-resistant vg using qPCR using a linearized genome plasmid as a standard124.  
 
Tissue preparation, immunohistochemistry and imaging  
 
Intravenous administration of AAV vectors was performed by injection into the retro-orbital 
sinus of adult mice (6-8 weeks of age). After allowing time for expression (3 weeks unless 
otherwise noted in Results), mice were anesthetized with EUTHASOL™ (Virbac) and 
transcardially perfused first with 0.1M phosphate buffer (PB, pH 7.4) at room temperature 
(RT) and then with freshly prepared, ice-cold 4% paraformaldehyde (PFA) in 0.1M PB. The 
tissues were post-fixed in 4% PFA overnight and afterwards transferred to phosphate 
buffered saline (PBS) with 0.05% sodium azide. The brains, lungs, and liver were sectioned 
to 100 µm, and the spinal cord to 300 µm, using a Leica VT1200 vibratome. 
Immunohistochemistry (IHC) was performed using 10% normal donkey serum (NDS), 0.1% 
Triton X-100 (no detergent was used with GAD67 staining) and 0.05% sodium azide. 
Primary antibodies used were rabbit Calbindin (1:500; Abcam, ab11426), mouse NeuN 
(1:500; EMD, MAB377), rabbit S100 (1:500; Abcam ab868), rabbit tyrosine hydroxylase 
(1:500; Abcam, ab112), goat 5-HT (1:200; Immunostar, 20079), rabbit PGP9.5 (1:500; 
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Abcam, ab10404), and mouse GAD67 (1:250; EMD, MAB5406). Sections were incubated 
with primary antibodies in blocking solution (PBS with 10% NDS and 0.05% sodium azide) 
for 16-24 hrs at RT and then washed in PBS overnight and followed by secondary antibody 
incubation (Jackson Immuno Research, 711-166-152, 711-606-152, 715-166-150, or 715-
606-150) for 16-24 hrs at RT.  
The dorsal root ganglia were post-fixed in 4% PFA at 4o C overnight and then 
cryopreserved in 30% sucrose at 4o C overnight. Tissues were then embedded in OCT 
(Tissue-Tek, Torrance, CA, USA), frozen in 2-methybutane on dry ice and stored at -80 o C 
until sectioning. For cryosectioning, the DRGs were cut at a thickness of 16 µm using a Leica 
CM3050 and adhered to a Superfrost Plus microscope slide (Fisher Scientific, Tustin, CA, 
USA). Slides were stored at -80o C until staining. For DRG IHC, the slides were incubated 
in rabbit anti-PGP9.5 antibody (1:250, Abcam, ab10404) in blocking solution (10% horse 
serum, 0.1% triton X-100, and 0.02% sodium azide in PBS) overnight at RT. The next day, 
sections were incubated with fluorescence-conjugated secondary antibody for 1 hr at RT 
(Jackson Immuno Research, 711-606-152). Between each step, sections were thoroughly 
washed with PBS. ProLong gold, anti-fade mounting medium (P36941; Molecular Probe, 
Life Technologies, Carlsbad, CA, USA) was applied to the slide before coverslip mounting. 
The small intestines and colons were post-fixed in 4% PFA at 4o C overnight. Then 
the duodenum, jejunum, ileum, and proximal colon were sectioned and blocked in PBS with 
0.1% triton X-100, 3% bovine serum albumin, and 0.01% sodium azide overnight at RT. The 
next day, the tissue was incubated with the mouse on mouse blocking reagent (Vector 
Laboratories, MKB-2213) in PBS with 0.01% sodium azide at RT for 16 hours. Afterwards, 
the tissue was stained in the initial blocking solution with guinea pig anti-PGP9.5 antibody 
(1:100, Abcam, ab10410) and rabbit anti-s100 beta antibody (1:200, Abcam, ab52642) for 
48 hours and then washed in PBS with 0.01% sodium azide overnight. The secondary 
antibodies – goat anti-guinea pig Alexa 647 (A-21450) and goat anti-rabbit Alexa 555 (A-
21428) Molecular Probes, Life Technologies, Carlsbad, CA, USA) – were incubated in the 
initial blocking solution for 48 hours. Unbound antibodies were then washed out with PBS 
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with 0.01% sodium azide overnight. Finally, samples were incubated in a refractive matching 
solution RIMS5 solution for 6 hours before imaging.  
For Fig. 4b and g, samples were made transparent and mounted using ScaleS48. For 
Fig. 4a,d, Fig. 5c, Supplementary Fig. 5a,b, and Fig. 6b,c samples were made transparent 
and mounted using RIMS. All other samples were mounted with Prolong Diamond Antifade 
(ThermoFisher, P36965).  
For some images, the 16-bit green channel (GFP) gamma was adjusted to enable 
visualization of low and high expressing cells while avoiding oversaturation. In all cases, 
changes to contrast or gamma as well as microscope laser settings remained constant across 
sets of images that were directly compared. Images were acquired on a Zeiss LSM 780 
confocal microscope fitted with the following objectives: Fluar 5×/0.25 M27 Plan-
Apochromat 10×/0.45 M27 (working distance 2.0 mm), and Plan-Apochromat 25×/0.8 Imm 
Corr DIC M27 multi-immersion or Zeiss Axiozoom V16 with a 0.7× objective fitted with a 
Hamamatsu c11440 camera.    
 
Image processing and data analysis 
 
All image processing was performed using Zen Black 2012, Adobe Photoshop and Illustrator 
CC, ImageJ, neuTube Build 1.0z2016, and Bitplane Imaris 8.3, and custom-made scripts in 
Matlab. For data analysis, Microsoft Excel 2016, Matlab, Python, and GraphPad Prism 7.01 
were used. 
To mitigate any cross-talk between the 3 fluorescent proteins, linear unmixing was 
used (Fig. 4d). For a given imaging condition, the expected cross-talk between the three 
fluorophores was evaluated based on the emission and excitation spectra of each fluorophore. 
Then, for each pixel in the RGB image the corresponding unmixed signals were calculated 
using a non-negative least square fitting. 
Cell profiling was done using Imaris (Bitplane). To detect neuronal cell bodies from 
the image data, we manually analyzed cells in the cortex and striatum by drawing a region 
of interest (ROI) around each cell’s nucleus and intensity values were exported into 
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Microsoft Excel and Graphpad Prism for analysis. For analysis of the cerebellum, we 
developed a computational pipeline to facilitate the automation of the whole procedure, since 
the highly organized layout of Purkinje cells allowed for high accuracy automated counting 
(the true positive rate = 88.0% and the positive predictive value = 95.5% relative to manual 
detection)  
To detect neuronal cell bodies from the image data (Supplementary Fig. 2), we 
applied a circular Hough transform to the maximum projection of the image stack. Prior to 
this process, morphological filtering with a circular structural element was performed with 
the images to remove thin fibrous processes. Each circular region detected from the images 
was considered as a single cell body. To measure the ratio of GFP-positive cells and their 
intensity in the cerebellum, we applied the abovementioned cell-body detection method to 
the Calbindin channel to detect the soma of Purkinje cells and used this to define ROIs in the 
GFP channel. We then subtracted the background from each ROI to exclude the expression 
(or leakage) of GFPs in cytosol. The background was estimated by applying a 2D Gaussian 
smoothing kernel to each cell body image. Subsequently, the image was converted to binary, 
and the convex hull of the connected object therein was calculated. The objects whose area 
were smaller than 10% of the cell body were removed, and we considered the largest object 
as a nucleus of interest if there were more than one object. Nuclei with a mean intensity 
higher than 0.1 (the intensity rescaled to the range of 0-1) was counted as GFP-positive. The 
mean intensity of the nucleus was calculated by averaging the pixel values inside the object 
(Supplementary Fig. 1). 
The pipeline for automated cell body detection was also applied to other analyses 
(Supplementary Fig. 7 and Fig. 4f). To measure the density of labeled cells in the sparse-
labeling system (Supplementary Fig. 6), we applied the cell body detection method to the 
images and measured the density of detected cells by dividing the cell number by the area of 
the image. We also examined the distance between the neighboring cells; for each cell, all of 
the distances to other cells were calculated, and the minimum was selected as the distance to 
the closest neighbor. The values for all cells were then averaged for each region and 
condition. We used the same method to determine whether each cell expressed 1, 2, or 3 
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XPFs (Fig. 4f) in the one- and two-component labeling systems. To do this, after detecting 
each cell body, we collected all the normalized intensity values therein from each channel. If 
the mean intensity of the channel was above 0.1, we considered that this gene (color) was 
expressed in the cell. Counting the number of expressed channels in each cell, we calculated 
the fraction of cells according to the number of expressed gene types. 
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